<html lang="en" class="pb-page js" data-request-id="94d6eb03277a01a6-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6eb03277a01a6-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/XXiIDBNT7oURa7TKY1u0NDarMNDJhGX5OzgPkq3_sUPfskNumQyqjHm-2Ao3zQnECyH7npoOcJATqvk-oC0wxA=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6eb03277a01a6-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.7874055229727325"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="Specialties" content="Cardiology|Clinical Medicine|Nephrology|Endocrinology">
<meta name="topics" content="Diabetes|Chronic Kidney Disease|Cardiology General|Outpatient-Based Clinical Medicine">
<meta name="articleCategory" content="Research"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2200436","title":"Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes","category":"Research","type":"Original Article","topics":"Diabetes|Chronic Kidney Disease|Cardiology General|Outpatient-Based Clinical Medicine","specialties":"Cardiology|Clinical Medicine|Nephrology|Endocrinology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-09-22T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Cardiology|Clinical Medicine|Nephrology|Endocrinology\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Diabetes|Chronic Kidney Disease|Cardiology General|Outpatient-Based Clinical Medicine\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2200436","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6eb03277a01a6-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes"><meta name="dc.Creator" content="The GRADE Study Research Group"><meta name="dc.Description" content="Data are lacking on the comparative effectiveness of commonly used glucose-lowering medications, when added to metformin, with respect to microvascular and cardiovascular disease outcomes in person..."><meta name="Description" content="Data are lacking on the comparative effectiveness of commonly used glucose-lowering medications, when added to metformin, with respect to microvascular and cardiovascular disease outcomes in person..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-09-22"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2200436"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202209223871206"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMoa2200433"><meta name="dc.Relation" content="10.1056/NEJMe2210531"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2200436">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2200436">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2200436">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes | NEJM">
        <meta property="og:title" content="Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2200436">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/8520e487-5c63-4fe0-bca8-d216ceacc1b6/nejmoa2200436_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/8520e487-5c63-4fe0-bca8-d216ceacc1b6/nejmoa2200436_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Data are lacking on the comparative effectiveness of commonly used glucose-lowering
medications, when added to metformin, with respect to microvascular and cardiovascular
disease outcomes in person...">
        <meta name="twitter:description" content="Data are lacking on the comparative effectiveness of commonly used glucose-lowering
medications, when added to metformin, with respect to microvascular and cardiovascular
disease outcomes in person...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="1185">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2200436">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2200436">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;article:article:doi\:10.1056/NEJMoa2200436;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2022.387.issue-12;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2200436" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2200436" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2200436" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2200436" class="inputDoi"><input type="hidden" value="The GRADE Study Research Group" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;387:1075-1088" class="inputCitation"><input type="hidden" value="09-21-2022" class="inputEPubDate"><input type="hidden" value="September 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6eb03277a01a6-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Author</span>: <span role="list"><span property="author" typeof="Person" role="listitem">The GRADE Study Research Group<sup class="xref"><a href="#fn1" role="doc-noteref">*</a></sup></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">September 21, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">387</span></span>:<span property="pageStart">1075</span>-<span property="pageEnd">1088</span></div><div class="doi">DOI: 10.1056/NEJMoa2200436</div><div class="core-enumeration"><a href="/toc/nejm/387/12"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">387</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">12</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3D%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D12%26contentID%3D10.1056%252FNEJMoa2200436%26title%3DGlycemia%2BReduction%2Bin%2BType%2B2%2BDiabetes%2B%25E2%2580%2594%2BMicrovascular%2Band%2BCardiovascular%2BOutcomes%26publicationDate%3D09%252F22%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2200436" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3D%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D12%26contentID%3D10.1056%252FNEJMoa2200436%26title%3DGlycemia%2BReduction%2Bin%2BType%2B2%2BDiabetes%2B%25E2%2580%2594%2BMicrovascular%2Band%2BCardiovascular%2BOutcomes%26publicationDate%3D09%252F22%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/6efc923c-243c-4e4e-aee4-121eef8aadd5/nejmoa2200436.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2200436.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2200436" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2200436" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2200436.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Data are lacking on the comparative effectiveness of commonly used glucose-lowering medications, when added to metformin, with respect to microvascular and cardiovascular disease outcomes in persons with type 2 diabetes.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We assessed the comparative effectiveness of four commonly used glucose-lowering medications, added to metformin, in achieving and maintaining a glycated hemoglobin level of less than 7.0% in participants with type 2 diabetes. The randomly assigned therapies were insulin glargine U-100 (hereafter, glargine), glimepiride, liraglutide, and sitagliptin. Prespecified secondary outcomes with respect to microvascular and cardiovascular disease included hypertension and dyslipidemia, confirmed moderately or severely increased albuminuria or an estimated glomerular filtration rate of less than 60 ml per minute per 1.73 m<sup>2</sup> of body-surface area, diabetic peripheral neuropathy assessed with the Michigan Neuropathy Screening Instrument, cardiovascular events (major adverse cardiovascular events [MACE], hospitalization for heart failure, or an aggregate outcome of any cardiovascular event), and death. Hazard ratios are presented with 95% confidence limits that are not adjusted for multiple comparisons.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">During a mean 5.0 years of follow-up in 5047 participants, there were no material differences among the interventions with respect to the development of hypertension or dyslipidemia or with respect to microvascular outcomes; the mean overall rate (i.e., events per 100 participant-years) of moderately increased albuminuria levels was 2.6, of severely increased albuminuria levels 1.1, of renal impairment 2.9, and of diabetic peripheral neuropathy 16.7. The treatment groups did not differ with respect to MACE (overall rate, 1.0), hospitalization for heart failure (0.4), death from cardiovascular causes (0.3), or all deaths (0.6). There were small differences with respect to rates of any cardiovascular disease, with 1.9, 1.9, 1.4, and 2.0 in the glargine, glimepiride, liraglutide, and sitagliptin groups, respectively. When one treatment was compared with the combined results of the other three treatments, the hazard ratios for any cardiovascular disease were 1.1 (95% confidence interval [CI], 0.9 to 1.3) in the glargine group, 1.1 (95% CI, 0.9 to 1.4) in the glimepiride group, 0.7 (95% CI, 0.6 to 0.9) in the liraglutide group, and 1.2 (95% CI, 1.0 to 1.5) in the sitagliptin group.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In participants with type 2 diabetes, the incidences of microvascular complications and death were not materially different among the four treatment groups. The findings indicated possible differences among the groups in the incidence of any cardiovascular disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; GRADE ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT01794143" target="_blank">NCT01794143</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Long-term complications of type 2 diabetes mellitus, including microvascular and cardiovascular disease, account for most illness, deaths, and costs associated with this condition.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> Clinical trials have shown a benefit of decreased chronic hyperglycemia on diabetes-specific microvascular complications.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r3" id="body-ref-r3" href-manipulated="true">2,3</a></sup> In addition, trials have shown that some new classes of glucose-lowering medication have beneficial effects with respect to cardiovascular disease and kidney disease, largely in participants with preexisting disease,<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r5 r6" id="body-ref-r6-1" href-manipulated="true">4-6</a></sup> whereas other medications have been shown to have neutral effects<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7" href-manipulated="true" aria-label="Reference 7">7</a></sup> or potentially harmful side effects.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r8 r9" id="body-ref-r9-1" href-manipulated="true">6,8,9</a></sup></div><div role="paragraph">The primary aim of the randomized Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness (GRADE) Study was to compare the effectiveness of agents from four commonly used classes of glucose-lowering medications, when added to metformin, in achieving and maintaining glycemic targets in participants with type 2 diabetes mellitus of recent onset.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-1" href-manipulated="true" aria-label="Reference 10">10</a></sup> These medications were insulin glargine U-100 (hereafter, glargine), the sulfonylurea glimepiride, the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide, and the dipeptidyl peptidase 4 inhibitor sitagliptin.</div><div role="paragraph">The metabolic results of this trial are presented in our accompanying article in this issue of the <i>Journal</i>.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-1" href-manipulated="true" aria-label="Reference 11">11</a></sup> In brief, glargine and liraglutide were more effective than glimepiride and sitagliptin in maintaining glycemic targets, albeit with small differences in the glycated hemoglobin level over time. The relative effects of the randomized therapies on prespecified secondary outcomes (microvascular complications and cardiovascular events and their risk factors) and heterogeneity among subgroups are presented here.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">The general description of this trial and its methods is provided in the companion article.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-2" href-manipulated="true" aria-label="Reference 11">11</a></sup> Here, we present a summary of the overall methods and additional methods relevant to the secondary outcomes. A full list of the inclusion and exclusion criteria is provided in the <a href="#ap1">protocol</a>, available with the full text of this article at NEJM.org. All the data were collected and analyzed by the research group. The authors vouch for the accuracy and completeness of the data and the fidelity of the trial to the <a href="#ap1">protocol</a>. The authors wrote the manuscript and made the decision to submit it for publication. No confidentiality restrictions were imposed by the funding agencies (including the National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK] of the National Institutes of Health) or by the companies that donated materials for the trial.</div><div role="paragraph">This trial was conducted at 36 clinical centers (Section S1 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org) and was designed by a subgroup of the investigators with NIDDK participation. In this parallel-group, comparative-effectiveness clinical trial, glucose-lowering medications approved by the Food and Drug Administration (FDA) were administered in accordance with their labeling, in combination with metformin.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-2" href-manipulated="true" aria-label="Reference 10">10</a></sup> Randomization was conducted with the use of a centralized Web-based system and stratified according to trial site. The participants and clinic staff were aware of the treatment assignments; however, investigators at the laboratories and reading centers and the event adjudicators were unaware of the treatment assignments. The manufacturers contributed trial medications under clinical-trial agreements with the NIDDK but had no role in the design, conduct, or analysis of the trial. An NIDDK-appointed data and safety monitoring board oversaw the conduct of the trial, and all participating centers received approval from local institutional review boards.</div></section><section id="sec-1-2"><h3>Participants</h3><div role="paragraph">The eligibility criteria and baseline characteristics of the participants have been published previously.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-1" href-manipulated="true" aria-label="Reference 12">12</a></sup> In brief, we enrolled 5047 patients who had received a diagnosis of type 2 diabetes mellitus at 30 years of age or older, with the exception of American Indians and Alaska Natives, in whom the age at diagnosis was 20 years or older. Eligibility criteria included the following: diabetes that had been diagnosed within the previous 10 years and treated with at least 500 mg of metformin per day, but no other glucose-lowering medications, and a glycated hemoglobin level of 6.8 to 8.5% (50.8 to 69.4 mmol per mole) at the time of randomization. The criteria for exclusion included a history of a major cardiovascular event in the year before randomization, a New York Heart Association functional classification of III or higher, and an estimated glomerular filtration rate (eGFR) of less than 30 ml per minute per 1.73 m<sup>2</sup> of body-surface area.</div></section><section id="sec-1-3"><h3>Treatments</h3><div role="paragraph">Participants were randomly assigned to receive one of the four treatments (glargine, glimepiride, liraglutide, or sitagliptin) in addition to metformin. The medications selected had to be FDA-approved for use in combination with metformin and in common clinical use at the time of the trial launch. During the run-in period before randomization, the metformin dose was increased to at least 1000 mg per day, with a target maximal dose (one that could be taken without unacceptable side effects) of 2000 mg per day. Immediate-release or extended-release formulations of metformin (Bristol Myers Squibb) were supplied to all the participants. The doses of the randomly assigned treatments were adjusted on the basis of their labeling. Glargine (Sanofi) was administered daily at an initial dose of up to 20 U and was adjusted on the basis of glucose levels monitored by the participants and to avoid hypoglycemia. The dose of glimepiride (Sanofi) was increased from 1 to 2 mg to a maximum of 8 mg per day, administered in divided doses, on the basis of glucose levels monitored by the participants and to avoid hypoglycemia. The dose of liraglutide (Novo Nordisk) was escalated to a maximum dose of 1.8 mg daily, depending on gastrointestinal side effects, and sitagliptin (Merck) at a dose of 100 mg was administered and adjusted depending on the participant’s kidney function.</div><div role="paragraph">During the trial, updated consensus recommendations on the choice of glucose-lowering medications in participants with prevalent cardiovascular or kidney disease were issued by the American Diabetes Association and the European Association for the Study of Diabetes.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r14" id="body-ref-r14" href-manipulated="true">13,14</a></sup> These recommendations were communicated to participants who were potentially eligible for these interventions and to their health care providers. The participants’ own health care providers were responsible for all medications other than the glucose-lowering medications specified in the trial protocol.</div></section><section id="sec-1-4"><h3>Outcomes and Assessments</h3><div role="paragraph">The participants were evaluated every 3 months. The metabolic outcomes for the current trial are described in detail in the accompanying article.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-3" href-manipulated="true" aria-label="Reference 11">11</a></sup> Data on the risk factors, microvascular complications, and cardiovascular outcomes that are the focus of this article were obtained with the use of standardized questionnaires, physical examinations, and laboratory analyses. Details regarding laboratory tests and other methods are provided in Sections S3 and S4 in the <a href="#ap2">Supplementary Appendix</a>. Risk factors related to the microvascular and cardiovascular outcomes included hypertension, defined as previously diagnosed hypertension, measured blood pressure of at least 140/90 mm Hg, or treatment with blood pressure–lowering agents, and dyslipidemia. Dyslipidemia was defined as fasting low-density lipoprotein cholesterol levels of at least 100 mg per deciliter (≥2.6 mmol per liter), triglyceride levels of at least 150 mg per deciliter (≥1.7 mmol per liter), high-density lipoprotein levels of less than 40 mg per deciliter (&lt;1.0 mmol per liter) in men and less than 50 mg per deciliter (&lt;1.3 mmol per liter) in women, or the use of lipid-lowering medications.</div><div role="paragraph">Kidney complications were assessed on the basis of the urinary albumin:creatinine ratio, which was measured every 6 months. Moderately increased albuminuria was defined as an albumin:creatinine ratio of 30 or greater, with albumin measured in milligrams and creatinine in grams, and confirmed at a subsequent visit. Severely increased albuminuria was defined as an albumin:creatinine ratio of 300 or higher. The eGFR was calculated from annual serum creatinine measurements, with renal impairment defined<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> as an eGFR of less than 60 ml per minute per 1.73 m<sup>2</sup>. Participants in whom incident end-stage kidney disease (as defined by dialysis, transplantation, or death from kidney disease) developed during the trial were considered to have had an outcome event in the categories of albuminuria (moderately increased albuminuria and severely increased albuminuria) and renal impairment. Diabetic peripheral neuropathy was assessed annually with the modified Michigan Neuropathy Screening Instrument (MNSI), which included a 15-item interviewer-administered symptom questionnaire and a bilateral lower-extremity clinical examination assessing ankle reflexes and vibration sensation at the great toes.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16-1" href-manipulated="true" aria-label="Reference 16">16</a></sup> Scores on the MNSI range from 0 to 8, with higher scores indicating more severe symptoms of neuropathy. Diabetic peripheral neuropathy was defined as an MNSI score of 7 or higher or an examination score of 2.5 or higher, as previously described.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16-2" href-manipulated="true" aria-label="Reference 16">16</a></sup></div><div role="paragraph">Cardiovascular outcomes were classified and adjudicated by a committee whose members were unaware of the treatment assignments, according to the 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17" href-manipulated="true" aria-label="Reference 17">17</a></sup> Two committee members independently reviewed each event and, if consensus could not be reached, a third member provided the tie-breaking assessment. A major adverse cardiovascular event (MACE) was defined as the time to the first nonfatal myocardial infarction or stroke or death from cardiovascular causes. The outcome “any cardiovascular disease” included the first incidence of any of the following: MACE, unstable angina or heart failure warranting hospitalization, or revascularization in any arterial bed.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">The statistical methods used herein are the same as those described in the companion article.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-4" href-manipulated="true" aria-label="Reference 11">11</a></sup> With the exception of sensitivity analyses conducted in accordance with the protocol, all analyses were conducted in accordance with the intention-to-treat principle. Briefly, analyses of the nine outcomes were conducted with the use of standard methods for the analysis of event–time (survival) data, including hazard ratios and confidence limits from the Cox proportional-hazards model, and the comparison of each group with the other three groups combined. For an outcome requiring confirmation, time to the initial event was used. Short-term (1 year) and longer-term (4 years) changes in risk factors were assessed in longitudinal models that compared the differences among treatment groups in the average (least-squares mean) over 1 and 4 years, the latter time when 85.8% of the cohort was under follow-up owing to staggered entry. No treatment-by-visit interaction was observed. Analyses of the cumulative incidence of hypertension, dyslipidemia, and microvascular outcomes excluded participants with those conditions at baseline, whereas analyses of incident cardiovascular disease included all the participants, regardless of history of cardiovascular disease before the trial.</div><div role="paragraph">Estimates of pairwise treatment effects from Cox models are presented as hazard ratios with 95% confidence intervals. The widths of the confidence intervals have not been adjusted for multiple testing, and therefore any inferences drawn from these intervals may not be reproducible. No P values are reported.</div><div role="paragraph">Per-protocol sensitivity analyses were used to assess the effect of the trial medications while the participants were receiving their assigned medication. This was accomplished by including results only for participants who continued to take their assigned glucose-lowering medications and who did not take glucose-lowering medications other than those that were part of the trial regimen. For each of the microvascular and cardiovascular outcomes, subgroup analyses were conducted according to prespecified factors, including race, ethnic group, sex, baseline glycated hemoglobin level (by strata in thirds), age, duration of diabetes, and body-mass index (Section S5 in the <a href="#ap2">Supplementary Appendix</a>).</div><div role="paragraph">With a projected hazard rate of 0.04 events per year for moderately increased albuminuria, we estimated that 5000 participants would provide the trial with 88% power to detect a 33% relative difference in risk among the groups. During the trial, the observed rate was less at 0.0275 per year, resulting in 71% power for this outcome. For any cardiovascular disease, we estimated that a rate of 0.01 per year would provide 72% power to detect a 50% difference among the groups. The observed rate was higher (0.018 per year), resulting in 99% power to detect a 50% difference.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Baseline Characteristics of the Participants</h3><div role="paragraph">The first of 5047 participants underwent randomization in July 2013, and enrollment concluded in August 2017. The baseline characteristics of the trial cohort have been reported previously,<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-2" href-manipulated="true" aria-label="Reference 12">12</a></sup> including those relevant to the microvascular and cardiovascular outcomes<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> (Table S1). At baseline, the mean (±SD) age of the trial cohort was 57.2±10.0 years, and 41.5% of the participants were 60 years of age or older. A total of 63.6% of the participants were men, which reflected the inclusion of 10 Veterans Affairs medical centers as trial recruitment sites.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-3" href-manipulated="true" aria-label="Reference 12">12</a></sup> A total of 65.7% of the participants identified as White, 19.8% as Black, and 3.6% as Asian; 0.6% of the participants identified as Hawaiian Islander or Pacific Islander, 2.7% as American Indian or Alaska Native, and 18.6% as Hispanic or Latinx. The mean duration of diabetes as reported by the participants was 4.2±2.7 years, and the daily metformin dose was 1994±205 mg. The mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 34.3±6.8, and the mean glycated hemoglobin level was 7.5±0.5% (58.3±5.3 mmol per mole).</div><div role="paragraph">At baseline, the prevalence of hypertension and dyslipidemia, largely indicated by the use of medications, was 77% and 96%, respectively. The prevalence of diabetic peripheral neuropathy at baseline was 42%, and 6.4% of the participants reported having had a heart attack or stroke. The baseline characteristics of the recruited cohort resembled those of the U.S. population who had metformin-treated type 2 diabetes mellitus and who were of a similar age and had a similar duration of diabetes and range of glycated hemoglobin levels (Table S2). Randomization was effective, with similar baseline demographic and clinical characteristics among the treatment groups.</div><div role="paragraph">The trial cohort was followed until April 2021, with a mean (and median) follow-up of 5.0 years (interquartile range, 4.1 to 6.0; range, 0 to 7.6). Data on recruitment and enrollment are provided in Figure S1 in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-2-2"><h3>Metabolic Outcomes, Hypertension, and Dyslipidemia</h3><div role="paragraph">Glargine and liraglutide were more effective than glimepiride and sitagliptin in the maintenance of glycemic targets (the primary metabolic outcome). The glycated hemoglobin level at 4 years was 7.1% in both the glargine and liraglutide groups, as compared with 7.2% in the sitagliptin group and 7.3% in the glimepiride group.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-5" href-manipulated="true" aria-label="Reference 11">11</a></sup></div><div role="paragraph"><a href="#f1">Figure 1</a> shows the cumulative incidence of hypertension among the 1168 of 5047 participants (23%) who did not have hypertension at baseline and the cumulative incidence of dyslipidemia among the 195 participants (4%) who did not have dyslipidemia at baseline. More than 60% of the participants who did not have hypertension at baseline and more than 90% of those who did not have dyslipidemia at baseline were later classified as having these conditions, largely because blood-pressure medications or lipid-lowering medications had been initiated. During the first year of follow-up, hypertension developed in approximately 25% of the participants who had not had hypertension previously, and this incidence reached approximately 60% by 6 years. Across the treatment groups, the curves separated beyond 1 year, with the glimepiride and glargine groups having the highest cumulative incidence of hypertension and the liraglutide group the lowest.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200436_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200436_f1.jpg"><img src="/cms/10.1056/NEJMoa2200436/asset/8520e487-5c63-4fe0-bca8-d216ceacc1b6/assets/images/large/nejmoa2200436_f1.jpg" height="1185" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Cumulative Incidences of Hypertension and Dyslipidemia in the Intention-to-Treat Analyses.</div><div class="notes"><div role="doc-footnote">Shown are the cumulative incidences of hypertension (Panel A) and dyslipidemia (Panel B) over 6.5 years of follow-up among participants who did not have each condition at baseline. The numbers plotted below the x axis of each panel are the numbers of participants at risk for the outcome at each follow-up time point (i.e., the number of participants in whom a specified outcome event had not developed by that time). Participants who had the condition at baseline were excluded, leaving 1168 of 5047 participants (23%) in the analysis of hypertension and 195 of 5047 participants (4%) in the analysis of dyslipidemia. There was no substantial difference among the groups with respect to the cumulative incidences of hypertension or dyslipidemia.</div></div></figcaption></figure></div><div role="paragraph">The average (least-squares mean) systolic blood pressure in all the participants over years 1 and 4 was highest in the glargine and glimepiride groups (129.1 mm Hg and 128.7 mm Hg, respectively), lowest in the liraglutide group (126.9 mm Hg), and intermediate in the sitagliptin group (128.1 mm Hg). Diastolic blood pressure did not differ according to treatment group. We also assessed differences among the treatment groups with respect to other risk factors over the short term (1 year) as compared with those over the long term (4 years). In the liraglutide group, the use of blood pressure–lowering medications increased from 80% in year 1 to 83% in year 4; in the other groups, the use of these medications ranged from 81 to 84% at year 1 and increased to 90 to 91% by year 4. Only approximately 10% of the participants without dyslipidemia at baseline had dyslipidemia in the first year, and this percentage increased to approximately 80% by year 4, with little subsequent increase.</div></section><section id="sec-2-3"><h3>Microvascular Outcomes</h3><div role="paragraph"><a href="#f2">Figure 2</a> shows the cumulative incidences of confirmed moderately increased albuminuria levels (albumin:creatinine ratio ≥30 [as measured in milligrams of albumin to grams of creatinine] on two consecutive visits), severely increased albuminuria levels (albumin:creatinine ratio ≥300, an eGFR of less than 60 ml per minute per 1.73 m<sup>2</sup>, and diabetic peripheral neuropathy (assessed by the MNSI). For each outcome, <a href="#t1">Table 1</a> shows the rates, pairwise hazard ratios between the treatment groups, and hazard ratios for each agent as compared with the others combined. There were no major differences among the treatment groups in the cumulative incidence of a confirmed moderately increased or severely increased albuminuria level or renal impairment (eGFR, &lt;60 ml per minute per 1.73 m<sup>2</sup> of body-surface area), with overall incidence rates of 2.57, 1.08, and 2.91 events per 100 participant-years, respectively; the cumulative incidences were approximately 15%, 8%, and 20%, respectively, by the end of the trial. Likewise, there were no major differences among the groups in the incidence of diabetic peripheral neuropathy. The overall linearized hazard rate was 16.7 events per 100 participant-years, with diabetic peripheral neuropathy developing in approximately 20% of the participants over the first year of follow-up and reaching approximately 70% by the end of the trial.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200436_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200436_f2.jpg"><img src="/cms/10.1056/NEJMoa2200436/asset/30af31dc-345b-4104-a222-d2b019323c27/assets/images/large/nejmoa2200436_f2.jpg" height="2248" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Cumulative Incidences of Microvascular Outcomes in the Intention-to-Treat Analyses.</div><div class="notes"><div role="doc-footnote">Shown are the cumulative incidences of the following conditions over 6.5 years of follow-up among participants who did not have one of these conditions at baseline: confirmed moderately increased albuminuria level (≥30 mg of albumin per gram of creatinine) or dialysis, transplantation, or death due to end-stage kidney disease (Panel A); severely increased albuminuria level (≥300 mg of albumin per gram of creatinine) or dialysis, transplantation, or death due to end-stage kidney disease (Panel B); renal impairment (estimated glomerular filtration rate of &lt;60 ml per minute per 1.73 m<sup>2</sup> of body-surface area) (Panel C); and diabetic peripheral neuropathy (Panel D). The numbers plotted below the x axis of each panel are the participants at risk for the outcome at each follow-up time point (i.e., the number of participants in whom a specified outcome event had not developed by that time). The insets show the same data on an enlarged y axis.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200436_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200436_t1.jpg"><img src="/cms/10.1056/NEJMoa2200436/asset/7dae3cf4-6282-4c0e-acf5-33d81a528abb/assets/images/large/nejmoa2200436_t1.jpg" height="3307" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">Glargine<br>(N=1263)</th><th class="txxx-borders">Glimepiride<br>(N=1254)</th><th class="txxx-borders">Liraglutide<br>(N=1262)</th><th class="txxx-borders">Sitagliptin<br>(N=1268)</th><th class="txxr-borders">Total<br>(N=5047)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Moderately increased albuminuria level<a href="#t1fn2" role="doc-noteref">†</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders">136/1066 (12.8)</td><td class="xxxx-borders">135/1046 (12.9)</td><td class="xxxx-borders">121/1040 (11.6)</td><td class="xxxx-borders">115/1070 (10.7)</td><td class="xxxr-borders">507/4222 (12.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Rate (95% CI) — events/100 participant-yr</td><td class="xxxx-borders shading">2.76 (2.32–3.26)</td><td class="xxxx-borders shading">2.78 (2.33–3.29)</td><td class="xxxx-borders shading">2.46 (2.05–2.95)</td><td class="xxxx-borders shading">2.30 (1.90–2.76)</td><td class="xxxr-borders shading">2.57 (2.35–2.81)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glargine</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1.00 (0.78–1.26)</td><td class="xxxx-borders shading">1.12 (0.88–1.43)</td><td class="xxxx-borders shading">1.20 (0.94–1.54)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glimepiride</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1.12 (0.88–1.44)</td><td class="xxxx-borders">1.21 (0.94–1.55)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Liraglutide</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" data-xml-align="center">1.07 (0.83–1.39)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Sitagliptin</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xxxx-borders shading">1.10 (0.91–1.34)</td><td class="xxxx-borders shading">1.11 (0.91–1.35)</td><td class="xxxx-borders shading">0.95 (0.77–1.16)</td><td class="xxxx-borders shading">0.86 (0.70–1.06)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Severely increased albuminuria level<a href="#t1fn3" role="doc-noteref">‡</a></b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders shading">59/1240 (4.8)</td><td class="xxxx-borders shading">64/1220 (5.2)</td><td class="xxxx-borders shading">70/1229 (5.7)</td><td class="xxxx-borders shading">66/1246 (5.3)</td><td class="xxxr-borders shading">259/4935 (5.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Rate (95% CI) — events/100 participant-yr</td><td class="xxxx-borders">0.97 (0.74–1.26)</td><td class="xxxx-borders">1.08 (0.83–1.38)</td><td class="xxxx-borders">1.17 (0.91–1.48)</td><td class="xxxx-borders">1.09 (0.85–1.39)</td><td class="xxxr-borders">1.08 (0.95–1.22)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glargine</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.90 (0.63–1.28)</td><td class="xxxx-borders">0.83 (0.59–1.18)</td><td class="xxxx-borders">0.89 (0.63–1.26)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glimepiride</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.92 (0.66–1.29)</td><td class="xxxx-borders shading">0.99 (0.70–1.39)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Liraglutide</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders" data-xml-align="center">1.07 (0.76–1.50)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Sitagliptin</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xxxx-borders">0.87 (0.65–1.17)</td><td class="xxxx-borders">1.00 (0.76–1.33)</td><td class="xxxx-borders">1.12 (0.85–1.47)</td><td class="xxxx-borders">1.02 (0.77–1.35)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Renal impairment<a href="#t1fn4" role="doc-noteref">§</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders">144/1174 (12.3)</td><td class="xxxx-borders">151/1198 (12.6)</td><td class="xxxx-borders">170/1184 (14.4)</td><td class="xxxx-borders">145/1208 (12.0)</td><td class="xxxr-borders">610/4764 (12.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Rate (95% CI) — events/100 participant-yr</td><td class="xxxx-borders shading">2.78 (2.35–3.28)</td><td class="xxxx-borders shading">2.88 (2.44–3.38)</td><td class="xxxx-borders shading">3.26 (2.79–3.78)</td><td class="xxxx-borders shading">2.73 (2.31–3.22)</td><td class="xxxr-borders shading">2.91 (2.69–3.15)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glargine</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.96 (0.76–1.20)</td><td class="xxxx-borders shading">0.85 (0.69–1.07)</td><td class="xxxx-borders shading">1.02 (0.81–1.28)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glimepiride</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.89 (0.72–1.11)</td><td class="xxxx-borders">1.07 (0.85–1.34)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Liraglutide</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" data-xml-align="center">1.19 (0.95–1.49)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Sitagliptin</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xxxx-borders shading">0.94 (0.78–1.13)</td><td class="xxxx-borders shading">1.00 (0.83–1.20)</td><td class="xxxx-borders shading">1.16 (0.97–1.38)</td><td class="xxxx-borders shading">0.92 (0.76–1.11)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Diabetic peripheral</b> <b>neuropathy</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders shading">393/751 (52.3)</td><td class="xxxx-borders shading">427/728 (58.7)</td><td class="xxxx-borders shading">382/704 (54.3)</td><td class="xxxx-borders shading">405/723 (56.0)</td><td class="xxxr-borders shading">1607/2906 (55.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Rate (95% CI) — events/100 participant-yr</td><td class="xxxx-borders">15.57 (14.07–17.19)</td><td class="xxxx-borders">18.22 (16.53–20.04)</td><td class="xxxx-borders">16.06 (14.49–17.75)</td><td class="xxxx-borders">16.87 (15.27–18.60)</td><td class="xxxr-borders">16.66 (15.85–17.49)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glargine</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.85 (0.74–0.97)</td><td class="xxxx-borders">0.96 (0.84–1.11)</td><td class="xxxx-borders">0.92 (0.80–1.06)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glimepiride</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1.14 (0.99–1.31)</td><td class="xxxx-borders shading">1.08 (0.95–1.24)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Liraglutide</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders" data-xml-align="center">0.95 (0.83–1.10)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Sitagliptin</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xbxx-borders">0.91 (0.81–1.02)</td><td class="xbxx-borders">1.13 (1.01–1.27)</td><td class="xbxx-borders">0.96 (0.85–1.07)</td><td class="xbxx-borders">1.02 (0.91–1.14)</td><td class="xbxr-borders">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Microvascular Outcomes in the Intention-to-Treat Analysis.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">The number of participants at risk excludes the prevalent cases at baseline that were not counted in either the numerator or denominator of the calculation of the rate. Pairwise hazard ratios were calculated from an analysis of the differences in the hazards among any of the four treatment groups, on the basis of a Cox proportional-hazards model, with treatment group as the only predictor variable. The 95% confidence intervals (CIs) were not corrected for multiple comparisons.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">A moderately increased albuminuria level was defined as a confirmed urinary albumin:creatinine ratio of at least 30, as measured in milligrams of albumin to grams of creatinine.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">A severely increased albuminuria level was defined as a urinary albumin:creatinine ratio of at least 300, as measured in milligrams of albumin to grams of creatinine.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Impaired renal function was defined as an estimated glomerular filtration rate of less than 60 ml per minute per 1.73 m<sup>2</sup>. Participants in whom incident end-stage kidney disease (as defined by dialysis, transplantation, or death from kidney disease) developed during the trial were considered to have had an outcome event in the categories of albuminuria (moderately increased albuminuria and severely increased albuminuria) and renal impairment.</div></div></div></figcaption></figure></div></section><section id="sec-2-4"><h3>Cardiovascular Outcomes</h3><div role="paragraph">The incidences of cardiovascular events and death are shown in <a href="#f3">Figure 3A</a> and <a href="#t2">Table 2</a>. The trialwide rate of the aggregate of any cardiovascular event was 1.79 events per 100 participant-years, with the incidence reaching 10 to 15% among the treatment groups by the end of the trial. As shown in <a href="#f3">Figure 3A</a>, the liraglutide group had few cases of any cardiovascular event over the first year, and the cumulative incidence increased linearly thereafter, whereas the other treatment groups appeared to have a linear increase starting from baseline and reaching approximately 14% at trial end, as compared with approximately 10% with liraglutide. In pairwise analyses, the hazard ratio for any cardiovascular disease in the liraglutide group as compared with the sitagliptin group was 0.68 (95% confidence interval [CI], 0.51 to 0.90), and the hazard ratio in the liraglutide group as compared with the glimepiride group was 0.71 (95% CI, 0.53 to 0.93), which was obtained by inverting the hazard ratio in the glimepiride group as compared with the liraglutide group (1.41) (<a href="#t2">Table 2</a>). The incidence of any cardiovascular disease was similar in the liraglutide and glargine groups. A comparison of the liraglutide group with the other three groups combined revealed a hazard ratio of 0.71 (95% CI, 0.56 to 0.90).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 3</div><nav><a href="#f3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200436_f3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f3" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200436_f3.jpg"><img src="/cms/10.1056/NEJMoa2200436/asset/1ba49ff9-e36b-4fba-a94e-e53a181c5476/assets/images/large/nejmoa2200436_f3.jpg" height="3343" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Cumulative Incidences of Cardiovascular Outcomes and Mortality in the Intention-to-Treat Analyses.</div><div class="notes"><div role="doc-footnote">Shown are the cumulative incidences of any cardiovascular disease (Panel A), a major adverse cardiovascular event (MACE) (Panel B), hospitalization for heart failure (Panel C), death from cardiovascular causes (Panel D), and death from any cause (Panel E) over 6.5 years of follow-up. The numbers plotted below the x axis of each panel are the participants at risk for the outcome at each follow-up time point (i.e., the number of participants in whom a specified outcome event had not developed by that time).</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200436_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200436_t2.jpg"><img src="/cms/10.1056/NEJMoa2200436/asset/7008d4df-93a9-4998-a55b-03c77c67ad6c/assets/images/large/nejmoa2200436_t2.jpg" height="3438" width="1970" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">Glargine<br>(N=1263)</th><th class="txxx-borders">Glimepiride<br>(N=1254)</th><th class="txxx-borders">Liraglutide<br>(N=1262)</th><th class="txxx-borders">Sitagliptin<br>(N=1268)</th><th class="txxr-borders">Total<br>(N=5047)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Any cardiovascular disease<a href="#t2fn2" role="doc-noteref">†</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders">113/1257 (9.0)</td><td class="xxxx-borders">115/1247 (9.2)</td><td class="xxxx-borders">83/1251 (6.6)</td><td class="xxxx-borders">121/1264 (9.6)</td><td class="xxxr-borders">432/5019 (8.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Rate (95% CI)</td><td class="xxxx-borders shading">1.87 (1.54–2.25)</td><td class="xxxx-borders shading">1.92 (1.59–2.31)</td><td class="xxxx-borders shading">1.36 (1.08–1.69)</td><td class="xxxx-borders shading">2.00 (1.66–2.39)</td><td class="xxxr-borders shading">1.79 (1.62–1.96)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glargine</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.97 (0.75–1.26)</td><td class="xxxx-borders shading">1.37 (1.03–1.82)</td><td class="xxxx-borders shading">0.93 (0.72–1.21)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glimepiride</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1.41 (1.07–1.87)</td><td class="xxxx-borders">0.96 (0.74–1.24)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Liraglutide</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" data-xml-align="center">0.68 (0.51–0.90)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Sitagliptin</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xxxx-borders shading">1.07 (0.87–1.33)</td><td class="xxxx-borders shading">1.12 (0.90–1.39)</td><td class="xxxx-borders shading">0.71 (0.56–0.90)</td><td class="xxxx-borders shading">1.18 (0.96–1.46)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>MACE</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders shading">65/1257 (5.2)</td><td class="xxxx-borders shading">59/1247 (4.7)</td><td class="xxxx-borders shading">48/1251 (3.8)</td><td class="xxxx-borders shading">69/1264 (5.5)</td><td class="xxxr-borders shading">241/5019 (4.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Rate (95% CI)</td><td class="xxxx-borders">1.05 (0.81–1.34)</td><td class="xxxx-borders">0.96 (0.73–1.24)</td><td class="xxxx-borders">0.78 (0.57–1.03)</td><td class="xxxx-borders">1.12 (0.87–1.41)</td><td class="xxxr-borders">0.98 (0.86–1.11)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glargine</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1.09 (0.77–1.55)</td><td class="xxxx-borders">1.35 (0.93–1.96)</td><td class="xxxx-borders">0.94 (0.67–1.32)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glimepiride</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1.24 (0.85–1.81)</td><td class="xxxx-borders shading">0.86 (0.61–1.22)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Liraglutide</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders" data-xml-align="center">0.70 (0.48–1.01)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Sitagliptin</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xxxx-borders">1.12 (0.84–1.49)</td><td class="xxxx-borders">0.99 (0.74–1.33)</td><td class="xxxx-borders">0.75 (0.54–1.03)</td><td class="xxxx-borders">1.21 (0.91–1.60)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Hospitalization for heart failure</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders">26/1257 (2.1)</td><td class="xxxx-borders">30/1247 (2.4)</td><td class="xxxx-borders">14/1251 (1.1)</td><td class="xxxx-borders">30/1264 (2.4)</td><td class="xxxr-borders">100/5019 (2.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Rate (95% CI)</td><td class="xxxx-borders shading">0.42 (0.27–0.61)</td><td class="xxxx-borders shading">0.48 (0.33–0.69)</td><td class="xxxx-borders shading">0.22 (0.12–0.38)</td><td class="xxxx-borders shading">0.48 (0.32–0.68)</td><td class="xxxr-borders shading">0.40 (0.33–0.49)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glargine</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.86 (0.51–1.45)</td><td class="xxxx-borders shading">1.85 (0.96–3.55)</td><td class="xxxx-borders shading">0.87 (0.51–1.47)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glimepiride</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2.16 (1.14–4.06)</td><td class="xxxx-borders">1.01 (0.61–1.67)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Liraglutide</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" data-xml-align="center">0.47 (0.25–0.88)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Sitagliptin</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xxxx-borders shading">1.11 (0.70–1.76)</td><td class="xxxx-borders shading">1.36 (0.88–2.11)</td><td class="xxxx-borders shading">0.49 (0.28–0.86)</td><td class="xxxx-borders shading">1.35 (0.87–2.08)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Death from cardiovascular causes</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders shading">21/1257 (1.7)</td><td class="xxxx-borders shading">16/1247 (1.3)</td><td class="xxxx-borders shading">9/1251 (0.7)</td><td class="xxxx-borders shading">21/1264 (1.7)</td><td class="xxxr-borders shading">67/5019 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Rate (95% CI)</td><td class="xxxx-borders">0.33 (0.21–0.51)</td><td class="xxxx-borders">0.26 (0.15–0.42)</td><td class="xxxx-borders">0.14 (0.07–0.27)</td><td class="xxxx-borders">0.33 (0.21–0.51)</td><td class="xxxr-borders">0.27 (0.21–0.34)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glargine</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1.29 (0.67–2.47)</td><td class="xxxx-borders">2.30 (1.05–5.01)</td><td class="xxxx-borders">1.00 (0.55–1.82)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glimepiride</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1.78 (0.79–4.04)</td><td class="xxxx-borders shading">0.77 (0.40–1.48)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Liraglutide</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders" data-xml-align="center">0.43 (0.20–0.95)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Sitagliptin</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xxxx-borders">1.43 (0.85–2.43)</td><td class="xxxx-borders">1.02 (0.58–1.82)</td><td class="xxxx-borders">0.47 (0.23–0.95)</td><td class="xxxx-borders">1.44 (0.85–2.44)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Death from any cause</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders">42/1263 (3.3)</td><td class="xxxx-borders">43/1254 (3.4)</td><td class="xxxx-borders">27/1262 (2.1)</td><td class="xxxx-borders">41/1267 (3.2)</td><td class="xxxr-borders">153/5046 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Rate (95% CI)</td><td class="xxxx-borders shading">0.65 (0.47–0.87)</td><td class="xxxx-borders shading">0.67 (0.48–0.90)</td><td class="xxxx-borders shading">0.42 (0.27–0.60)</td><td class="xxxx-borders shading">0.63 (0.45–0.86)</td><td class="xxxr-borders shading">0.59 (0.50–0.69)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glargine</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.96 (0.63–1.46)</td><td class="xxxx-borders shading">1.54 (0.95–2.50)</td><td class="xxxx-borders shading">1.02 (0.66–1.57)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glimepiride</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1.61 (1.00–2.61)</td><td class="xxxx-borders">1.07 (0.69–1.63)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Liraglutide</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" data-xml-align="center">0.66 (0.41–1.07)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Sitagliptin</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xbxx-borders shading">1.15 (0.80–1.64)</td><td class="xbxx-borders shading">1.22 (0.85–1.73)</td><td class="xbxx-borders shading">0.64 (0.42–0.97)</td><td class="xbxx-borders shading">1.12 (0.78–1.60)</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Cardiovascular and Mortality Outcomes in the Intention-to-Treat Analysis.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">The number of participants at risk excludes the prevalent cases at baseline that were not counted in either the numerator or the denominator of the calculation of the rate. Pairwise hazard ratios were calculated from an analysis of the differences in the hazards among any of the four treatment groups, on the basis of a Cox proportional-hazards model, with treatment group as the only predictor variable. The 95% confidence intervals were not corrected for multiple comparisons.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Any cardiovascular disease was defined as the first of any major adverse cardiovascular event (MACE; defined as death from cardiovascular disease or nonfatal myocardial infarction or stroke), unstable angina warranting hospitalization or revascularization, heart failure warranting hospitalization, or any revascularization event.</div></div></div></figcaption></figure></div><div role="paragraph">The rate of MACE was approximately 0.98 events per 100 participant-years, with the cumulative incidence increasing steadily to approximately 6 to 8% across the treatment groups by the end of the trial, with no material differences among the groups. The rate of hospitalization for heart failure was low overall (0.4 per 100 participant-years), and although there were nominal differences in the hazard rates among the four treatment groups, the low number of events precluded a definitive assessment. A total of 67 participants died from cardiovascular disease and 153 participants died from any cause, with corresponding rates of 0.27 and 0.59 per 100 participant-years, respectively (<a href="#f3">Figure 3</a> and <a href="#t2">Table 2</a>). The incidences of death from cardiovascular causes and all deaths were similar among the groups.</div></section><section id="sec-2-5"><h3>Per-Protocol and Intention-to-Treat Analyses</h3><div role="paragraph">Per-protocol sensitivity analyses were performed and compared with the intention-to-treat analyses (Figs. S2 and S3 and Tables S3 and S4). There was no material difference among the treatment groups in the intention-to-treat analysis with respect to confirmed moderately increased albuminuria; however, the per-protocol analysis showed small differences favoring the liraglutide and sitagliptin groups over the glargine and glimepiride groups. The hazard ratios, which were were derived by inverting the ratios shown in Table S3, are as follows: hazard ratio in the liraglutide group as compared with the glargine group, 0.73; hazard ratio in the sitagliptin group as compared with the glargine group, 0.71; hazard ratio in the liraglutide group as compared with the glimepiride group, 0.73; and hazard ratio in the sitagliptin group as compared with the glimepiride group, 0.71.</div><div role="paragraph">There were no differences between the intention-to-treat and per-protocol analyses with respect to severely increased albuminuria level, renal impairment, or diabetic peripheral neuropathy. In the analyses of cardiovascular outcomes and death, in no instance did the per-protocol analysis yield materially larger differences among groups than did the intention-to-treat analysis. The differences among treatment groups with respect to any cardiovascular disease in the intention-to-treat analysis were unchanged in the per-protocol analysis.</div></section><section id="sec-2-6"><h3>Subgroup Analyses</h3><div role="paragraph">Assessments of the homogeneity of treatment-group differences among predefined subgroup strata showed that the pattern of risks across treatment groups did not differ materially across any subgroups (Table S5). A post hoc analysis showed a substantially higher incidence of any cardiovascular disease among the participants with a history of stroke or myocardial infarction at baseline than among those without this history; the rates of any cardiovascular disease were nominally lower in both categories in the liraglutide group than in the other three treatment groups.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">The current trial showed significant differences among the four randomized treatments, when added to metformin, in the ability to reach and maintain targeted glycated hemoglobin levels.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-6" href-manipulated="true" aria-label="Reference 11">11</a></sup> Here, we evaluated secondary outcomes, including differential effects of these agents with respect to microvascular and cardiovascular disease and their risk factors. Most participants had hypertension or dyslipidemia at baseline, which is typical for a population with type 2 diabetes mellitus. More than 90% of the participants who did not have hypertension or dyslipidemia at baseline were later classified as having these conditions, largely because medications had been initiated by their own care providers. The only difference in the development of these conditions at 1 and 4 years of follow-up was that liraglutide may have had a relative benefit with respect to measured blood pressure. The glargine group may have had more incident hypertension because of the effect of insulin on sodium reabsorption in the kidney.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19" href-manipulated="true" aria-label="Reference 19">19</a></sup></div><div role="paragraph">Despite the differences among the treatment groups in glycemia and hypertension, both of which are long-recognized risk factors for microvascular complications,<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r20" id="body-ref-r20" href-manipulated="true">2,20</a></sup> there were no material differences in any of the microvascular complications that were evaluated. The absence of the expected effect of lower glycemia on microvascular complications has been noted in some trials, including studies of diabetes prevention,<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21" href-manipulated="true" aria-label="Reference 21">21</a></sup> and this absence has been ascribed to inadequate separation of glycemic levels over time, insufficient trial duration, threshold effects,<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22" href-manipulated="true" aria-label="Reference 22">22</a></sup> or inadequate power. Any or all of these factors, including the small separation in glycemia,<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-7" href-manipulated="true" aria-label="Reference 11">11</a></sup> might have been operative in our trial.</div><div role="paragraph">The trial cohort was at relatively low risk for MACE or other cardiovascular events; only 6% of the participants had a history of myocardial infarction or stroke before the trial began, and none of the participants had had an event within 1 year before randomization. This trial was not designed or powered to detect differences among the treatment groups with respect to cardiovascular events or death from cardiovascular disease. Cardiovascular risk factors were generally well managed, so the observed differences in the incidence of any cardiovascular disease among the treatment groups are especially notable. Trials showing a beneficial effect of a number of GLP-1 receptor agonists with respect to cardiovascular disease have included populations with a higher cardiovascular risk at baseline than the population in the current trial.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r9 r23" id="body-ref-r23-1" href-manipulated="true">4,9,23</a></sup> Nevertheless, in our trial, there was a difference in the incidence of any cardiovascular disease across the four treatment groups and in pairwise comparisons between the liraglutide and sitagliptin groups, between the liraglutide and glimepiride groups, and between the liraglutide group and the other three groups combined. These results should not be viewed as definitive proof that GLP-1 receptor agonists reduce the incidence of cardiovascular disease in low-risk populations. However, our results parallel the benefits with respect to cardiovascular disease that have been reported in populations with type 2 diabetes mellitus and higher cardiovascular risk at baseline than the population in the current trial.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r9 r23" id="body-ref-r23-2" href-manipulated="true">4,9,23</a></sup></div><div role="paragraph">We observed differences among the groups in adherence to and discontinuation of the assigned medications such that there were some differences in the sensitivity analyses. In the per-protocol analysis, but not in the intention-to-treat analyses, the liraglutide and sitagliptin groups had a lower risk of moderate albuminuria than the glimepiride and glargine groups. However, liraglutide did not appear to mitigate decreases in renal function. In the comparison of liraglutide with the other three medications, the hazard ratio for an eGFR of less than 60 was 1.16 (95% CI, 0.97 to 1.38). In the per-protocol analyses, as in the intention-to-treat analyses, the risk of any cardiovascular disease was lower with liraglutide than with either glimepiride or sitagliptin.</div><div role="paragraph">The current trial used a comparative-effectiveness approach to examine four different glucose-lowering medications. The different effects of these agents on microvascular complications, cardiovascular risk factors, and cardiovascular outcomes should be considered along with their glycemic effects when choosing therapies for type 2 diabetes. In this trial involving participants with type 2 diabetes of generally brief duration, the incidences of microvascular complications and death were not materially different among the four treatment groups. The findings did provide support for possible differences among the treatment groups in the incidence of any cardiovascular disease.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="writing-committee" role="paragraph">The members of the writing committee (David M. Nathan, M.D., John M. Lachin, Sc.D., Ionut Bebu, Ph.D., Henry B. Burch, M.D., John B. Buse, M.D., Andrea L. Cherrington, M.D., Stephen P. Fortmann, M.D., Jennifer B. Green, M.D., Steven E. Kahn, M.B., Ch.B., M. Sue Kirkman, M.D., Heidi Krause-Steinrauf, M.S., Mary E. Larkin, R.N., Lawrence S. Phillips, M.D., Rodica Pop-Busui, M.D., Ph.D., Michael Steffes, M.D., Margaret Tiktin, D.N.P., Mark Tripputi, Ph.D., Deborah J. Wexler, M.D., and Naji Younes, Ph.D.) assume responsibility for the overall content and integrity of this article.</div><div data-type="disclaimer" role="paragraph">The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</div><div data-type="published/updated" role="paragraph">This article was updated on June 29, 2023, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by a grant (U01DK098246) from the <span class="named-content" data-type="funder">National Institute of Diabetes and Digestive and Kidney Diseases</span> (NIDDK) of the National Institutes of Health (NIH); a U34 planning grant (U34-DK-088043) from the NIDDK; funding for the initial planning meeting regarding the U34 proposal from the <span class="named-content" data-type="funder">American Diabetes Association</span>; the <span class="named-content" data-type="funder">National Heart, Lung, and Blood Institute</span>; the <span class="named-content" data-type="funder">Centers for Disease Control and Prevention</span>; resources and facilities from the Department of Veterans Affairs; grants (P30 DK017047, P30 DK020541-44, P30 DK020572, P30 DK072476, P30 DK079626, P30 DK092926, U54 GM104940, UL1 TR000170, UL1 TR000439, UL1 TR000445, UL1 TR001102, UL1 TR001108, UL1 TR001409, 2UL1TR001425, UL1 TR001449, UL1 TR002243, UL1 TR002345, UL1 TR002378, UL1 TR002489, UL1 TR002529, UL1 TR002535, UL1 TR002537, UL1 TR002541, and UL1 TR002548) from the NIH; educational materials from the National Diabetes Education Program; and donated medications and supplies from Becton Dickinson, Bristol Myers Squibb, Merck, Novo Nordisk, Roche Diagnostics, and Sanofi.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank our participants, whose loyal dedication made this trial possible.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2200436_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2200436/suppl_file/nejmoa2200436_protocol.pdf" download="nejmoa2200436_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2200436_protocol.pdf" data-doi="10.1056/NEJMoa2200436">Download</a></li><li>5.19 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2200436_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2200436/suppl_file/nejmoa2200436_appendix.pdf" download="nejmoa2200436_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2200436_appendix.pdf" data-doi="10.1056/NEJMoa2200436">Download</a></li><li>2.11 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2200436_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2200436/suppl_file/nejmoa2200436_disclosures.pdf" download="nejmoa2200436_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2200436_disclosures.pdf" data-doi="10.1056/NEJMoa2200436">Download</a></li><li>829.60 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2200436_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2200436/suppl_file/nejmoa2200436_data-sharing.pdf" download="nejmoa2200436_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2200436_data-sharing.pdf" data-doi="10.1056/NEJMoa2200436">Download</a></li><li>70.10 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. <em>Diabetes Care</em> 2018;41:917-928.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dci18-0007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29567642/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000430456100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Economic+costs+of+diabetes+in+the+U.S.+in+2017.&amp;publication_year=2018&amp;journal=Diabetes+Care&amp;pages=917-928&amp;doi=10.2337%2Fdci18-0007&amp;pmid=29567642" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). <em>Lancet</em> 1998;352:837-853.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(98)07019-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9742976/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000075857300006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intensive+blood-glucose+control+with+sulphonylureas+or+insulin+compared+with+conventional+treatment+and+risk+of+complications+in+patients+with+type+2+diabetes+%28UKPDS+33%29.&amp;publication_year=1998&amp;journal=Lancet&amp;pages=837-853&amp;doi=10.1016%2FS0140-6736%2898%2907019-6&amp;pmid=9742976" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] microvascular complications. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] factors for microvascular complications, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. <em>Cochrane Database Syst Rev</em> 2013;11:CD008143-CD008143.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24214280/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000327587700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+intensive+glycaemic+control+versus+targeting+conventional+glycaemic+control+for+type+2+diabetes+mellitus.&amp;publication_year=2013&amp;journal=Cochrane+Database+Syst+Rev&amp;pages=CD008143-CD008143&amp;pmid=24214280" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. <em>N Engl J Med</em> 2016;375:311-322.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_5_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200436&amp;key=10.1056%2FNEJMoa1603827&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27295427/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000380313200005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Liraglutide+and+cardiovascular+outcomes+in+type+2+diabetes.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=311-322&amp;doi=10.1056%2FNEJMoa1603827&amp;pmid=27295427" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in participants with preexisting disease, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] than the population in the current trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] than the population in the current trial. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. <em>N Engl J Med</em> 2015;373:2117-2128.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_6_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200436&amp;key=10.1056%2FNEJMoa1504720&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26378978/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365354800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Empagliflozin%2C+cardiovascular+outcomes%2C+and+mortality+in+type+2+diabetes.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=2117-2128&amp;doi=10.1056%2FNEJMoa1504720&amp;pmid=26378978" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. <em>N Engl J Med</em> 2017;377:644-657.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200436&amp;key=10.1056%2FNEJMoa1611925&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28605608/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407691400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Canagliflozin+and+cardiovascular+and+renal+events+in+type+2+diabetes.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=644-657&amp;doi=10.1056%2FNEJMoa1611925&amp;pmid=28605608" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in participants with preexisting disease, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] or potentially harmful side effects. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. <em>N Engl J Med</em> 2015;373:232-242.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_8_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200436&amp;key=10.1056%2FNEJMoa1501352&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26052984/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000357956200006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+sitagliptin+on+cardiovascular+outcomes+in+type+2+diabetes.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=232-242&amp;doi=10.1056%2FNEJMoa1501352&amp;pmid=26052984" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. <em>Lancet</em> 2005;366:1279-1289.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(05)67528-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16214598/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000232405700026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Secondary+prevention+of+macrovascular+events+in+patients+with+type+2+diabetes+in+the+PROactive+study+%28PROspective+pioglitAzone+Clinical+Trial+In+macroVascular+Events%29%3A+a+randomised+controlled+trial.&amp;publication_year=2005&amp;journal=Lancet&amp;pages=1279-1289&amp;doi=10.1016%2FS0140-6736%2805%2967528-9&amp;pmid=16214598" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. <em>N Engl J Med</em> 2016;375:1834-1844.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_10_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200436&amp;key=10.1056%2FNEJMoa1607141&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27633186/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387534200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Semaglutide+and+cardiovascular+outcomes+in+patients+with+type+2+diabetes.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=1834-1844&amp;doi=10.1056%2FNEJMoa1607141&amp;pmid=27633186" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] or potentially harmful side effects. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] than the population in the current trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] than the population in the current trial. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). <em>Diabetes Care</em> 2013;36:2254-2261.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc13-0356" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23690531/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000327252600038" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rationale+and+design+of+the+glycemia+reduction+approaches+in+diabetes%3A+a+comparative+effectiveness+study+%28GRADE%29.&amp;publication_year=2013&amp;journal=Diabetes+Care&amp;pages=2254-2261&amp;doi=10.2337%2Fdc13-0356&amp;pmid=23690531" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] type 2 diabetes mellitus of recent onset. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] labeling, in combination with metformin. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">GRADE Study Research Group. Glycemia reduction in type 2 diabetes — glycemic outcomes. <em>N Engl J Med</em> 2022;387:1067-1074.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000865461700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glycemia+reduction+in+type+2+diabetes+%E2%80%94+glycemic+outcomes.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=1067-1074" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Journal. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] is provided in the companion article. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in detail in the accompanying article. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] those described in the companion article. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] group and 7.3% in the glimepiride group. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] targeted glycated hemoglobin levels. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] including the small separation in glycemia, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Wexler DJ, Krause-Steinrauf H, Crandall JP, et al. Baseline characteristics of randomized participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <em>Diabetes Care</em> 2019;42:2098-2107.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc19-0901" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31391203/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491450200017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Baseline+characteristics+of+randomized+participants+in+the+Glycemia+Reduction+Approaches+in+Diabetes%3A+A+Comparative+Effectiveness+Study+%28GRADE%29.&amp;publication_year=2019&amp;journal=Diabetes+Care&amp;pages=2098-2107&amp;doi=10.2337%2Fdc19-0901&amp;pmid=31391203" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been published previously. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] trial cohort have been reported previously, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] medical centers as trial recruitment sites. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <em>Diabetes Care</em> 2018;41:2669-2701.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dci18-0033" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30291106/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450560000037" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Management+of+hyperglycemia+in+type+2+diabetes%2C+2018%3A+a+consensus+report+by+the+American+Diabetes+Association+%28ADA%29+and+the+European+Association+for+the+Study+of+Diabetes+%28EASD%29.&amp;publication_year=2018&amp;journal=Diabetes+Care&amp;pages=2669-2701&amp;doi=10.2337%2Fdci18-0033&amp;pmid=30291106" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <em>Diabetes Care</em> 2020;43:487-493.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dci19-0066" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31857443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000508199900043" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2019+Update+to%3A+management+of+hyperglycemia+in+type+2+diabetes%2C+2018%3A+a+consensus+report+by+the+American+Diabetes+Association+%28ADA%29+and+the+European+Association+for+the+Study+of+Diabetes+%28EASD%29.&amp;publication_year=2020&amp;journal=Diabetes+Care&amp;pages=487-493&amp;doi=10.2337%2Fdci19-0066&amp;pmid=31857443" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. <em>N Engl J Med</em> 2012;367:20-29.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_16_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200436&amp;key=10.1056%2FNEJMoa1114248&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22762315/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000305979400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Estimating+glomerular+filtration+rate+from+serum+creatinine+and+cystatin+C.&amp;publication_year=2012&amp;journal=N+Engl+J+Med&amp;pages=20-29&amp;doi=10.1056%2FNEJMoa1114248&amp;pmid=22762315" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. <em>Diabetes Care</em> 1994;17:1281-1289.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/diacare.17.11.1281" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7821168/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994PN84300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+practical+two-step+quantitative+clinical+and+electrophysiological+assessment+for+the+diagnosis+and+staging+of+diabetic+neuropathy.&amp;publication_year=1994&amp;journal=Diabetes+Care&amp;pages=1281-1289&amp;doi=10.2337%2Fdiacare.17.11.1281&amp;pmid=7821168" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and vibration sensation at the great toes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of 2.5 or higher, as previously described. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Hicks KA, Mahaffey KW, Mehran R, et al. 2017 Cardiovascular and stroke endpoint definitions for clinical trials. <em>Circulation</em> 2018;137:961-972.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/CIRCULATIONAHA.117.033502" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29483172/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000426206800011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2017+Cardiovascular+and+stroke+endpoint+definitions+for+clinical+trials.&amp;publication_year=2018&amp;journal=Circulation&amp;pages=961-972&amp;doi=10.1161%2FCIRCULATIONAHA.117.033502&amp;pmid=29483172" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Mather KJ, Bebu I, Baker C, et al. Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes — A Comparative Effectiveness (GRADE) study cohort. <em>Diabetes Res Clin Pract</em> 2020;165:108235-108235.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.diabres.2020.108235" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32450102/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000554922700015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prevalence+of+microvascular+and+macrovascular+disease+in+the+Glycemia+Reduction+Approaches+in+Diabetes+%E2%80%94+A+Comparative+Effectiveness+%28GRADE%29+study+cohort.&amp;publication_year=2020&amp;journal=Diabetes+Res+Clin+Pract&amp;pages=108235-108235&amp;doi=10.1016%2Fj.diabres.2020.108235&amp;pmid=32450102" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Sarafidis PA, Bakris GL. The antinatriuretic effect of insulin: an unappreciated mechanism for hypertension associated with insulin resistance? <em>Am J Nephrol</em> 2007;27:44-54.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1159/000098955" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17245074/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000244256400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+antinatriuretic+effect+of+insulin%3A+an+unappreciated+mechanism+for+hypertension+associated+with+insulin+resistance%3F&amp;publication_year=2007&amp;journal=Am+J+Nephrol&amp;pages=44-54&amp;doi=10.1159%2F000098955&amp;pmid=17245074" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. <em>BMJ</em> 1998;317:713-720.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/bmj.317.7160.713" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9732338/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000075995100019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+atenolol+and+captopril+in+reducing+risk+of+macrovascular+and+microvascular+complications+in+type+2+diabetes%3A+UKPDS+39.&amp;publication_year=1998&amp;journal=BMJ&amp;pages=713-720&amp;doi=10.1136%2Fbmj.317.7160.713&amp;pmid=9732338" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Nathan DM, Bennett PH, Crandall JP, et al. Does diabetes prevention translate into reduced long-term vascular complications of diabetes? <em>Diabetologia</em> 2019;62:1319-1328.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00125-019-4928-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31270584/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000475698900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Does+diabetes+prevention+translate+into+reduced+long-term+vascular+complications+of+diabetes%3F&amp;publication_year=2019&amp;journal=Diabetologia&amp;pages=1319-1328&amp;doi=10.1007%2Fs00125-019-4928-8&amp;pmid=31270584" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Zoungas S, Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. <em>Diabetologia</em> 2012;55:636-643.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00125-011-2404-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22186981/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000299921200013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+of+HbA1c+levels+with+vascular+complications+and+death+in+patients+with+type+2+diabetes%3A+evidence+of+glycaemic+thresholds.&amp;publication_year=2012&amp;journal=Diabetologia&amp;pages=636-643&amp;doi=10.1007%2Fs00125-011-2404-1&amp;pmid=22186981" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <em>Lancet</em> 2019;394:121-130.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(19)31149-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31189511/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000475393900025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dulaglutide+and+cardiovascular+outcomes+in+type+2+diabetes+%28REWIND%29%3A+a+double-blind%2C+randomised+placebo-controlled+trial.&amp;publication_year=2019&amp;journal=Lancet&amp;pages=121-130&amp;doi=10.1016%2FS0140-6736%2819%2931149-3&amp;pmid=31189511" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] than the population in the current trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] than the population in the current trial. </span></a></li></ul></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/387/12"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">387</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">12</span></span> • <span property="datePublished">September 22, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1075</span>-<span property="pageEnd">1088</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: September 21, 2022</div><div><b class="core-label">Published in issue</b>: September 22, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/cardiology-general" alt="View article keyword Cardiology General" data-interactiontype="article_recirculation_click">Cardiology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/chronic-kidney-disease" alt="View article keyword Chronic Kidney Disease" data-interactiontype="article_recirculation_click">Chronic Kidney Disease</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/diabetes" alt="View article keyword Diabetes" data-interactiontype="article_recirculation_click">Diabetes</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/outpatient-based-clinical-medicine" alt="View article keyword Outpatient-Based Clinical Medicine" data-interactiontype="article_recirculation_click">Outpatient-Based Clinical Medicine</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person">The GRADE Study Research Group<sup class="xref"><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Massachusetts General Hospital Diabetes Center, Harvard Medical School, Boston (D.M.N., M.E.L., D.J.W.); the Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Rockville (J.M.L., I.B., H.K.-S., M. Tripputi, N.Y.), and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (H.B.B.) — both in Maryland; the Division of Endocrinology and Metabolism, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill (J.B.B., M.S.K.), and the Department of Medicine, Duke Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Durham (J.B.G.) — both in North Carolina; the University of Alabama, Birmingham (A.L.C.); Kaiser Permanente Center for Health Research, Portland, OR (S.P.F.); the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, Veterans Affairs (VA) Puget Sound Health Care System, University of Washington, Seattle (S.E.K.); the Atlanta VA Medical Center, Decatur, GA (L.S.P.); the Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor (R.P.-B.); the Advanced Research and Diagnostic Laboratory, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis (M.S.); and the Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland (M. Tiktin).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Lachin can be contacted at <a href="mailto:grademail@bsc.gwu.edu">grademail@bsc.gwu.edu</a> or at the George Washington University Biostatistics Center–GRADE Coordinating Center, 6110 Executive Blvd., Ste. 750, Rockville, MD 20852.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">The members of the GRADE Study Research Group are listed in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">91</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2200436" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="4823e2d9-290e-46bc-ca01-b3363333f8e4"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136231934" style="display:inline-block;">
                <img alt="Article has an altmetric score of 363" src="https://badges.altmetric.com/?size=320&amp;score=363&amp;types=mbtttwf1" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136231934">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_4823e2d9-290e-46bc-ca01-b3363333f8e4" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136231934&amp;tab=news">
          Picked up by <b>38</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136231934&amp;tab=blogs">
          Blogged by <b>3</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136231934&amp;tab=twitter">
          Posted by <b>126</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136231934&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136231934&amp;tab=wikipedia">
          Referenced in <b>3</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136231934&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>284</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6eb03277a01a6-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2200436"> <input type="hidden" name="downloadFileName" value="csp_387_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2200436%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-12%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="91" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Orlagh U. Carroll, </li><li class="list-inline-item cited-by__entry__author">Patrick Bidulka, </li><li class="list-inline-item cited-by__entry__author">Anirban Basu, </li><li class="list-inline-item cited-by__entry__author">Amanda I. Adler, </li><li class="list-inline-item cited-by__entry__author">Stephen O'Neill, </li><li class="list-inline-item cited-by__entry__author">Andrew H. Briggs, </li><li class="list-inline-item cited-by__entry__author">David G. Lugo‐Palacios, </li><li class="list-inline-item cited-by__entry__author">Kamlesh Khunti, </li><li class="list-inline-item cited-by__entry__author">Richard Grieve, </li></ul><span class="cited-by__entry__title">
              Long‐term outcomes following alternative second‐line oral glucose‐lowering treatments: Results from the real‐world progression in type 2 diabetes mellitus United Kingdom (
              RAPIDS
              ‐
              UK
              ) model
            , </span><span class="cited-by__entry__series-title">Diabetes, Obesity and Metabolism, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/dom.16447" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/dom.16447</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/dom.16447" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Juan Yan, </li><li class="list-inline-item cited-by__entry__author">Xiaoying Sun, </li><li class="list-inline-item cited-by__entry__author">Xiaoyan Liu, </li><li class="list-inline-item cited-by__entry__author">Xiaoming Li, </li></ul><span class="cited-by__entry__title">Gastric filling ultrasound in assessing gastrointestinal motility in type 2 diabetic patients with neuropathy: A clinical study, </span><span class="cited-by__entry__series-title">Journal of Diabetes Investigation, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/jdi.70059" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/jdi.70059</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/jdi.70059" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Wenli Liu, </li><li class="list-inline-item cited-by__entry__author">Wenhua Gu, </li><li class="list-inline-item cited-by__entry__author">Junhui Chen, </li><li class="list-inline-item cited-by__entry__author">Ruobing Wang, </li><li class="list-inline-item cited-by__entry__author">Yaohua Shen, </li><li class="list-inline-item cited-by__entry__author">Zhaoyu Lu, </li><li class="list-inline-item cited-by__entry__author">Lei Zhang, </li></ul><span class="cited-by__entry__title">Global, regional and national epidemiology of anemia attributable to chronic kidney disease, 1990–2021, </span><span class="cited-by__entry__series-title">Clinical Kidney Journal, </span><span class="cited-by__entry__volume"><strong>18</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1093/ckj/sfaf138" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1093/ckj/sfaf138</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1093/ckj/sfaf138" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Deborah J. Wexler, </li><li class="list-inline-item cited-by__entry__author">W. Timothy Garvey, </li><li class="list-inline-item cited-by__entry__author">Alokananda Ghosh, </li><li class="list-inline-item cited-by__entry__author">Erin J. Kazemi, </li><li class="list-inline-item cited-by__entry__author">Heidi Krause-Steinrauf, </li><li class="list-inline-item cited-by__entry__author">Andrew J. Ahmann, </li><li class="list-inline-item cited-by__entry__author">Janet Brown-Friday, </li><li class="list-inline-item cited-by__entry__author">Sabina Casula, </li><li class="list-inline-item cited-by__entry__author">Andrea L. Cherrington, </li><li class="list-inline-item cited-by__entry__author">Tom A. Elasy, </li><li class="list-inline-item cited-by__entry__author">Stephen P. Fortmann, </li><li class="list-inline-item cited-by__entry__author">Jonathan A. Krakoff, </li><li class="list-inline-item cited-by__entry__author">Sunder Mudaliar, </li><li class="list-inline-item cited-by__entry__author">Margaret Tiktin, </li><li class="list-inline-item cited-by__entry__author">Naji Younes, </li><li class="list-inline-item cited-by__entry__author">JP Crandall, </li><li class="list-inline-item cited-by__entry__author">MD McKee, </li><li class="list-inline-item cited-by__entry__author">S Behringer-Massera, </li><li class="list-inline-item cited-by__entry__author">J Brown-Friday, </li><li class="list-inline-item cited-by__entry__author">E Xhori, </li><li class="list-inline-item cited-by__entry__author">K Ballentine-Cargill, </li><li class="list-inline-item cited-by__entry__author">S Duran, </li><li class="list-inline-item cited-by__entry__author">H Estrella, </li><li class="list-inline-item cited-by__entry__author">S Gonzalez de la torre, </li><li class="list-inline-item cited-by__entry__author">J Lukin, </li><li class="list-inline-item cited-by__entry__author">LS Phillips, </li><li class="list-inline-item cited-by__entry__author">E Burgess, </li><li class="list-inline-item cited-by__entry__author">D Olson, </li><li class="list-inline-item cited-by__entry__author">M Rhee, </li><li class="list-inline-item cited-by__entry__author">P Wilson, </li><li class="list-inline-item cited-by__entry__author">TS Raines, </li><li class="list-inline-item cited-by__entry__author">J Boers, </li><li class="list-inline-item cited-by__entry__author">J Costello, </li><li class="list-inline-item cited-by__entry__author">M Maher-Albertelli, </li><li class="list-inline-item cited-by__entry__author">R Mungara, </li><li class="list-inline-item cited-by__entry__author">L Savoye, </li><li class="list-inline-item cited-by__entry__author">CA White, </li><li class="list-inline-item cited-by__entry__author">C Gullett, </li><li class="list-inline-item cited-by__entry__author">L Holloway, </li><li class="list-inline-item cited-by__entry__author">F Morehead, </li><li class="list-inline-item cited-by__entry__author">S Person, </li><li class="list-inline-item cited-by__entry__author">M Sibymon, </li><li class="list-inline-item cited-by__entry__author">S Tanukonda, </li><li class="list-inline-item cited-by__entry__author">C Adams, </li><li class="list-inline-item cited-by__entry__author">A Ross, </li><li class="list-inline-item cited-by__entry__author">A Balasubramanyam, </li><li class="list-inline-item cited-by__entry__author">R Gaba, </li><li class="list-inline-item cited-by__entry__author">E Gonzalez Hattery, </li><li class="list-inline-item cited-by__entry__author">A Ideozu, </li><li class="list-inline-item cited-by__entry__author">J Jimenez, </li><li class="list-inline-item cited-by__entry__author">G Montes, </li><li class="list-inline-item cited-by__entry__author">C Wright, </li><li class="list-inline-item cited-by__entry__author">P Hollander, </li><li class="list-inline-item cited-by__entry__author">E Roe, </li><li class="list-inline-item cited-by__entry__author">A Jackson, </li><li class="list-inline-item cited-by__entry__author">A Smiley, </li><li class="list-inline-item cited-by__entry__author">P Burt, </li><li class="list-inline-item cited-by__entry__author">L Estrada, </li><li class="list-inline-item cited-by__entry__author">K Chionh, </li><li class="list-inline-item cited-by__entry__author">F Ismail-Beigi, </li><li class="list-inline-item cited-by__entry__author">C Falck-Ytter, </li><li class="list-inline-item cited-by__entry__author">L Sayyed Kassem, </li><li class="list-inline-item cited-by__entry__author">A Sood, </li><li class="list-inline-item cited-by__entry__author">M Tiktin, </li><li class="list-inline-item cited-by__entry__author">T Kulow, </li><li class="list-inline-item cited-by__entry__author">C Newman, </li><li class="list-inline-item cited-by__entry__author">KA Stancil, </li><li class="list-inline-item cited-by__entry__author">B Cramer, </li><li class="list-inline-item cited-by__entry__author">J Iacoboni, </li><li class="list-inline-item cited-by__entry__author">MV Kononets, </li><li class="list-inline-item cited-by__entry__author">C Sanders, </li><li class="list-inline-item cited-by__entry__author">L Tucker, </li><li class="list-inline-item cited-by__entry__author">A Werner, </li><li class="list-inline-item cited-by__entry__author">A Maxwell, </li><li class="list-inline-item cited-by__entry__author">G McPhee, </li><li class="list-inline-item cited-by__entry__author">C Patel, </li><li class="list-inline-item cited-by__entry__author">L Colosimo, </li><li class="list-inline-item cited-by__entry__author">A Krol, </li><li class="list-inline-item cited-by__entry__author">R Goland, </li><li class="list-inline-item cited-by__entry__author">J Pring, </li><li class="list-inline-item cited-by__entry__author">L Alfano, </li><li class="list-inline-item cited-by__entry__author">P Kringas, </li><li class="list-inline-item cited-by__entry__author">C Hausheer, </li><li class="list-inline-item cited-by__entry__author">J Tejada, </li><li class="list-inline-item cited-by__entry__author">K Gumpel, </li><li class="list-inline-item cited-by__entry__author">A Kirpitch, </li><li class="list-inline-item cited-by__entry__author">H Schneier, </li><li class="list-inline-item cited-by__entry__author">JB Green, </li><li class="list-inline-item cited-by__entry__author">H AbouAssi, </li><li class="list-inline-item cited-by__entry__author">R Chatterjee, </li><li class="list-inline-item cited-by__entry__author">MN Feinglos, </li><li class="list-inline-item cited-by__entry__author">J English Jones, </li><li class="list-inline-item cited-by__entry__author">SA Khan, </li><li class="list-inline-item cited-by__entry__author">JB Kimpel, </li><li class="list-inline-item cited-by__entry__author">RP Zimmer, </li><li class="list-inline-item cited-by__entry__author">M Furst, </li><li class="list-inline-item cited-by__entry__author">BM Satterwhite, </li><li class="list-inline-item cited-by__entry__author">CR Thacker, </li><li class="list-inline-item cited-by__entry__author">K Evans Kreider, </li><li class="list-inline-item cited-by__entry__author">CN Mariash, </li><li class="list-inline-item cited-by__entry__author">KJ Mather, </li><li class="list-inline-item cited-by__entry__author">HM Ismail, </li><li class="list-inline-item cited-by__entry__author">A Lteif, </li><li class="list-inline-item cited-by__entry__author">T Hamilton, </li><li class="list-inline-item cited-by__entry__author">N Patel, </li><li class="list-inline-item cited-by__entry__author">G Riera, </li><li class="list-inline-item cited-by__entry__author">M Jackson, </li><li class="list-inline-item cited-by__entry__author">V Pirics, </li><li class="list-inline-item cited-by__entry__author">D Aguillar, </li><li class="list-inline-item cited-by__entry__author">D Howard, </li><li class="list-inline-item cited-by__entry__author">S Hurt, </li><li class="list-inline-item cited-by__entry__author">R Bergenstal, </li><li class="list-inline-item cited-by__entry__author">A Carlson, </li><li class="list-inline-item cited-by__entry__author">T Martens, </li><li class="list-inline-item cited-by__entry__author">M Johnson, </li><li class="list-inline-item cited-by__entry__author">R Hill, </li><li class="list-inline-item cited-by__entry__author">J Hyatt, </li><li class="list-inline-item cited-by__entry__author">C Jensen, </li><li class="list-inline-item cited-by__entry__author">M Madden, </li><li class="list-inline-item cited-by__entry__author">D Martin, </li><li class="list-inline-item cited-by__entry__author">H Willis, </li><li class="list-inline-item cited-by__entry__author">W Konerza, </li><li class="list-inline-item cited-by__entry__author">S Yang, </li><li class="list-inline-item cited-by__entry__author">K Kleeberger, </li><li class="list-inline-item cited-by__entry__author">R Passi, </li><li class="list-inline-item cited-by__entry__author">S Fortmann, </li><li class="list-inline-item cited-by__entry__author">M Herson, </li><li class="list-inline-item cited-by__entry__author">K Mularski, </li><li class="list-inline-item cited-by__entry__author">H Glauber, </li><li class="list-inline-item cited-by__entry__author">J Prihoda, </li><li class="list-inline-item cited-by__entry__author">B Ash, </li><li class="list-inline-item cited-by__entry__author">C Carlson, </li><li class="list-inline-item cited-by__entry__author">PA Ramey, </li><li class="list-inline-item cited-by__entry__author">E Schield, </li><li class="list-inline-item cited-by__entry__author">B Torgrimson-Ojerio, </li><li class="list-inline-item cited-by__entry__author">K Arnold, </li><li class="list-inline-item cited-by__entry__author">B Kauffman, </li><li class="list-inline-item cited-by__entry__author">E Panos, </li><li class="list-inline-item cited-by__entry__author">S Sahnow, </li><li class="list-inline-item cited-by__entry__author">K Bays, </li><li class="list-inline-item cited-by__entry__author">K Berame, </li><li class="list-inline-item cited-by__entry__author">J Cook, </li><li class="list-inline-item cited-by__entry__author">D Ghioni, </li><li class="list-inline-item cited-by__entry__author">J Gluth, </li><li class="list-inline-item cited-by__entry__author">K Schell, </li><li class="list-inline-item cited-by__entry__author">J Criscola, </li><li class="list-inline-item cited-by__entry__author">C Friason, </li><li class="list-inline-item cited-by__entry__author">S Jones, </li><li class="list-inline-item cited-by__entry__author">S Nazarov, </li><li class="list-inline-item cited-by__entry__author">J Barzilay, </li><li class="list-inline-item cited-by__entry__author">N Rassouli, </li><li class="list-inline-item cited-by__entry__author">R Puttnam, </li><li class="list-inline-item cited-by__entry__author">B Ojoawo, </li><li class="list-inline-item cited-by__entry__author">R Nelson, </li><li class="list-inline-item cited-by__entry__author">M Curtis, </li><li class="list-inline-item cited-by__entry__author">B Hollis, </li><li class="list-inline-item cited-by__entry__author">C Sanders-Jones, </li><li class="list-inline-item cited-by__entry__author">K Stokes, </li><li class="list-inline-item cited-by__entry__author">Z El-Haqq, </li><li class="list-inline-item cited-by__entry__author">A Kolli, </li><li class="list-inline-item cited-by__entry__author">T Tran, </li><li class="list-inline-item cited-by__entry__author">D Wexler, </li><li class="list-inline-item cited-by__entry__author">ME Larkin, </li><li class="list-inline-item cited-by__entry__author">J Meigs, </li><li class="list-inline-item cited-by__entry__author">B Chambers, </li><li class="list-inline-item cited-by__entry__author">A Dushkin, </li><li class="list-inline-item cited-by__entry__author">G Rocchio, </li><li class="list-inline-item cited-by__entry__author">M Yepes, </li><li class="list-inline-item cited-by__entry__author">B Steiner, </li><li class="list-inline-item cited-by__entry__author">H Dulin, </li><li class="list-inline-item cited-by__entry__author">M Cayford, </li><li class="list-inline-item cited-by__entry__author">K Chu, </li><li class="list-inline-item cited-by__entry__author">A DeManbey, </li><li class="list-inline-item cited-by__entry__author">M Hillard, </li><li class="list-inline-item cited-by__entry__author">K Martin, </li><li class="list-inline-item cited-by__entry__author">N Thangthaeng, </li><li class="list-inline-item cited-by__entry__author">L Gurry, </li><li class="list-inline-item cited-by__entry__author">R Kochis, </li><li class="list-inline-item cited-by__entry__author">E Raymond, </li><li class="list-inline-item cited-by__entry__author">V Ripley, </li><li class="list-inline-item cited-by__entry__author">C Stevens, </li><li class="list-inline-item cited-by__entry__author">J Park, </li><li class="list-inline-item cited-by__entry__author">V Aroda, </li><li class="list-inline-item cited-by__entry__author">A Ghazi, </li><li class="list-inline-item cited-by__entry__author">M Magee, </li><li class="list-inline-item cited-by__entry__author">Ann Ressing, </li><li class="list-inline-item cited-by__entry__author">A Loveland, </li><li class="list-inline-item cited-by__entry__author">M Hamm, </li><li class="list-inline-item cited-by__entry__author">M Hurtado, </li><li class="list-inline-item cited-by__entry__author">A Kuhn, </li><li class="list-inline-item cited-by__entry__author">J Leger, </li><li class="list-inline-item cited-by__entry__author">L Manandhar, </li><li class="list-inline-item cited-by__entry__author">F Mwicigi, </li><li class="list-inline-item cited-by__entry__author">O Sanchez, </li><li class="list-inline-item cited-by__entry__author">T Young, </li><li class="list-inline-item cited-by__entry__author">R Garg, </li><li class="list-inline-item cited-by__entry__author">V Lagari-Libhaber, </li><li class="list-inline-item cited-by__entry__author">HJ Florez, </li><li class="list-inline-item cited-by__entry__author">WM Valencia, </li><li class="list-inline-item cited-by__entry__author">J Marks, </li><li class="list-inline-item cited-by__entry__author">S Casula, </li><li class="list-inline-item cited-by__entry__author">L Oropesa-Gonzalez, </li><li class="list-inline-item cited-by__entry__author">L Hue, </li><li class="list-inline-item cited-by__entry__author">A Cuadot, </li><li class="list-inline-item cited-by__entry__author">R Nieto-Martinez, </li><li class="list-inline-item cited-by__entry__author">AK Riccio Veliz, </li><li class="list-inline-item cited-by__entry__author">M Gutt, </li><li class="list-inline-item cited-by__entry__author">YJ Kendal, </li><li class="list-inline-item cited-by__entry__author">B. Veciana, </li><li class="list-inline-item cited-by__entry__author">A Ahmann, </li><li class="list-inline-item cited-by__entry__author">D Aby-Daniel, </li><li class="list-inline-item cited-by__entry__author">F Joarder, </li><li class="list-inline-item cited-by__entry__author">V Morimoto, </li><li class="list-inline-item cited-by__entry__author">C Sprague, </li><li class="list-inline-item cited-by__entry__author">D Yamashita, </li><li class="list-inline-item cited-by__entry__author">N Cady, </li><li class="list-inline-item cited-by__entry__author">N Rivera-Eschright, </li><li class="list-inline-item cited-by__entry__author">P Kirchhoff, </li><li class="list-inline-item cited-by__entry__author">B Morales Gomez, </li><li class="list-inline-item cited-by__entry__author">J Adducci, </li><li class="list-inline-item cited-by__entry__author">A Goncharova, </li><li class="list-inline-item cited-by__entry__author">SH Hox, </li><li class="list-inline-item cited-by__entry__author">H Petrovitch, </li><li class="list-inline-item cited-by__entry__author">M Matwichyna, </li><li class="list-inline-item cited-by__entry__author">V Jenkins, </li><li class="list-inline-item cited-by__entry__author">L Broadwater, </li><li class="list-inline-item cited-by__entry__author">RR Ishii, </li><li class="list-inline-item cited-by__entry__author">NO Bermudez, </li><li class="list-inline-item cited-by__entry__author">DS Hsia, </li><li class="list-inline-item cited-by__entry__author">WT Cefalu, </li><li class="list-inline-item cited-by__entry__author">FL Greenway, </li><li class="list-inline-item cited-by__entry__author">C Waguespack, </li><li class="list-inline-item cited-by__entry__author">E King, </li><li class="list-inline-item cited-by__entry__author">G Fry, </li><li class="list-inline-item cited-by__entry__author">A Dragg, </li><li class="list-inline-item cited-by__entry__author">B Gildersleeve, </li><li class="list-inline-item cited-by__entry__author">J Arceneaux, </li><li class="list-inline-item cited-by__entry__author">N Haynes, </li><li class="list-inline-item cited-by__entry__author">A Thomassie, </li><li class="list-inline-item cited-by__entry__author">M Pavlionis, </li><li class="list-inline-item cited-by__entry__author">B Bourgeois, </li><li class="list-inline-item cited-by__entry__author">C Hazlett, </li><li class="list-inline-item cited-by__entry__author">S Mudaliar, </li><li class="list-inline-item cited-by__entry__author">R Henry, </li><li class="list-inline-item cited-by__entry__author">S Boeder, </li><li class="list-inline-item cited-by__entry__author">J Pettus, </li><li class="list-inline-item cited-by__entry__author">E Diaz, </li><li class="list-inline-item cited-by__entry__author">D Garcia-Acosta, </li><li class="list-inline-item cited-by__entry__author">S Maggs, </li><li class="list-inline-item cited-by__entry__author">C DeLue, </li><li class="list-inline-item cited-by__entry__author">A Stallings, </li><li class="list-inline-item cited-by__entry__author">E Castro, </li><li class="list-inline-item cited-by__entry__author">S Hernandez, </li><li class="list-inline-item cited-by__entry__author">J Krakoff, </li><li class="list-inline-item cited-by__entry__author">JM Curtis, </li><li class="list-inline-item cited-by__entry__author">T Killean, </li><li class="list-inline-item cited-by__entry__author">M Khalid, </li><li class="list-inline-item cited-by__entry__author">E Joshevama, </li><li class="list-inline-item cited-by__entry__author">E Diaz, </li><li class="list-inline-item cited-by__entry__author">D Martin, </li><li class="list-inline-item cited-by__entry__author">K Tsingine, </li><li class="list-inline-item cited-by__entry__author">T Karshner, </li><li class="list-inline-item cited-by__entry__author">J Albu, </li><li class="list-inline-item cited-by__entry__author">FX Pi-Sunyer, </li><li class="list-inline-item cited-by__entry__author">S Frances, </li><li class="list-inline-item cited-by__entry__author">C Maggio, </li><li class="list-inline-item cited-by__entry__author">E Ellis, </li><li class="list-inline-item cited-by__entry__author">J Bastawrose, </li><li class="list-inline-item cited-by__entry__author">X Gong, </li><li class="list-inline-item cited-by__entry__author">MA Banerji, </li><li class="list-inline-item cited-by__entry__author">P August, </li><li class="list-inline-item cited-by__entry__author">M Lee, </li><li class="list-inline-item cited-by__entry__author">D Lorber, </li><li class="list-inline-item cited-by__entry__author">NM Brown, </li><li class="list-inline-item cited-by__entry__author">DH Josephson, </li><li class="list-inline-item cited-by__entry__author">LL Thomas, </li><li class="list-inline-item cited-by__entry__author">M Tsovian, </li><li class="list-inline-item cited-by__entry__author">A Cherian, </li><li class="list-inline-item cited-by__entry__author">MH Jacobson, </li><li class="list-inline-item cited-by__entry__author">MM Mishko, </li><li class="list-inline-item cited-by__entry__author">MS Kirkman, </li><li class="list-inline-item cited-by__entry__author">JB Buse, </li><li class="list-inline-item cited-by__entry__author">J Diner, </li><li class="list-inline-item cited-by__entry__author">J Dostou, </li><li class="list-inline-item cited-by__entry__author">S Machineni, </li><li class="list-inline-item cited-by__entry__author">L Young, </li><li class="list-inline-item cited-by__entry__author">K Bergamo, </li><li class="list-inline-item cited-by__entry__author">A Goley, </li><li class="list-inline-item cited-by__entry__author">J Kerr, </li><li class="list-inline-item cited-by__entry__author">JF Largay, </li><li class="list-inline-item cited-by__entry__author">S Guarda, </li><li class="list-inline-item cited-by__entry__author">J Cuffee, </li><li class="list-inline-item cited-by__entry__author">D Culmer, </li><li class="list-inline-item cited-by__entry__author">R Fraser, </li><li class="list-inline-item cited-by__entry__author">H Almeida, </li><li class="list-inline-item cited-by__entry__author">S Coffer, </li><li class="list-inline-item cited-by__entry__author">E Debnam, </li><li class="list-inline-item cited-by__entry__author">L Kiker, </li><li class="list-inline-item cited-by__entry__author">S Morton, </li><li class="list-inline-item cited-by__entry__author">K Josey, </li><li class="list-inline-item cited-by__entry__author">G Fuller, </li><li class="list-inline-item cited-by__entry__author">WT Garvey, </li><li class="list-inline-item cited-by__entry__author">AL Cherrington, </li><li class="list-inline-item cited-by__entry__author">D Dyer, </li><li class="list-inline-item cited-by__entry__author">MCR Lawson, </li><li class="list-inline-item cited-by__entry__author">O Griffith, </li><li class="list-inline-item cited-by__entry__author">A Agne, </li><li class="list-inline-item cited-by__entry__author">S McCullars, </li><li class="list-inline-item cited-by__entry__author">RM Cohen, </li><li class="list-inline-item cited-by__entry__author">J Craig, </li><li class="list-inline-item cited-by__entry__author">MC Rogge, </li><li class="list-inline-item cited-by__entry__author">K Burton, </li><li class="list-inline-item cited-by__entry__author">K Kersey, </li><li class="list-inline-item cited-by__entry__author">C Wilson, </li><li class="list-inline-item cited-by__entry__author">S Lipp, </li><li class="list-inline-item cited-by__entry__author">MB Vonder Meulen, </li><li class="list-inline-item cited-by__entry__author">C Adkins, </li><li class="list-inline-item cited-by__entry__author">T Onadeko, </li><li class="list-inline-item cited-by__entry__author">N Rasouli, </li><li class="list-inline-item cited-by__entry__author">C Baker, </li><li class="list-inline-item cited-by__entry__author">E Schroeder, </li><li class="list-inline-item cited-by__entry__author">M Razzaghi, </li><li class="list-inline-item cited-by__entry__author">C Lyon, </li><li class="list-inline-item cited-by__entry__author">R Penaloza, </li><li class="list-inline-item cited-by__entry__author">C Underkofler, </li><li class="list-inline-item cited-by__entry__author">R Lorch, </li><li class="list-inline-item cited-by__entry__author">S Douglass, </li><li class="list-inline-item cited-by__entry__author">S Steiner, </li><li class="list-inline-item cited-by__entry__author">WI Sivitz, </li><li class="list-inline-item cited-by__entry__author">E Cline, </li><li class="list-inline-item cited-by__entry__author">LK Knosp, </li><li class="list-inline-item cited-by__entry__author">J McConnell, </li><li class="list-inline-item cited-by__entry__author">T Lowe, </li><li class="list-inline-item cited-by__entry__author">WH Herman, </li><li class="list-inline-item cited-by__entry__author">R Pop-Busui, </li><li class="list-inline-item cited-by__entry__author">MH Tan, </li><li class="list-inline-item cited-by__entry__author">C Martin, </li><li class="list-inline-item cited-by__entry__author">A Waltje, </li><li class="list-inline-item cited-by__entry__author">A Katona, </li><li class="list-inline-item cited-by__entry__author">L Goodhall, </li><li class="list-inline-item cited-by__entry__author">R Eggleston, </li><li class="list-inline-item cited-by__entry__author">S Kuo, </li><li class="list-inline-item cited-by__entry__author">S Bojescu, </li><li class="list-inline-item cited-by__entry__author">S Bule, </li><li class="list-inline-item cited-by__entry__author">N Kessler, </li><li class="list-inline-item cited-by__entry__author">E LaSalle, </li><li class="list-inline-item cited-by__entry__author">K Whitley, </li><li class="list-inline-item cited-by__entry__author">ER Seaquist, </li><li class="list-inline-item cited-by__entry__author">A Bantle, </li><li class="list-inline-item cited-by__entry__author">T Harindhanavudhi, </li><li class="list-inline-item cited-by__entry__author">A Kumar, </li><li class="list-inline-item cited-by__entry__author">B Redmon, </li><li class="list-inline-item cited-by__entry__author">J Bantle, </li><li class="list-inline-item cited-by__entry__author">M Coe, </li><li class="list-inline-item cited-by__entry__author">M Mech, </li><li class="list-inline-item cited-by__entry__author">A Taddese, </li><li class="list-inline-item cited-by__entry__author">L Lesne, </li><li class="list-inline-item cited-by__entry__author">S Smith, </li><li class="list-inline-item cited-by__entry__author">C Desouza, </li><li class="list-inline-item cited-by__entry__author">L Kuechenmeister, </li><li class="list-inline-item cited-by__entry__author">V Shivaswamy, </li><li class="list-inline-item cited-by__entry__author">S Burbach, </li><li class="list-inline-item cited-by__entry__author">MG Rodriguez, </li><li class="list-inline-item cited-by__entry__author">K Seipel, </li><li class="list-inline-item cited-by__entry__author">A Alfred, </li><li class="list-inline-item cited-by__entry__author">AL Morales, </li><li class="list-inline-item cited-by__entry__author">J Eggert, </li><li class="list-inline-item cited-by__entry__author">G Lord, </li><li class="list-inline-item cited-by__entry__author">W Taylor, </li><li class="list-inline-item cited-by__entry__author">R Tillson, </li><li class="list-inline-item cited-by__entry__author">DS Schade, </li><li class="list-inline-item cited-by__entry__author">A Adolphe, </li><li class="list-inline-item cited-by__entry__author">M Burge, </li><li class="list-inline-item cited-by__entry__author">E Duran-Valdez, </li><li class="list-inline-item cited-by__entry__author">J Martinez, </li><li class="list-inline-item cited-by__entry__author">A Bancroft, </li><li class="list-inline-item cited-by__entry__author">S Kunkel, </li><li class="list-inline-item cited-by__entry__author">F Ali Jamaleddin Ahmad, </li><li class="list-inline-item cited-by__entry__author">D Hernandez McGinnis, </li><li class="list-inline-item cited-by__entry__author">B Pucchetti, </li><li class="list-inline-item cited-by__entry__author">E Scripsick, </li><li class="list-inline-item cited-by__entry__author">A Zamorano, </li><li class="list-inline-item cited-by__entry__author">RA DeFronzo, </li><li class="list-inline-item cited-by__entry__author">E Cersosimo, </li><li class="list-inline-item cited-by__entry__author">M Abdul-Ghani, </li><li class="list-inline-item cited-by__entry__author">C Triplitt, </li><li class="list-inline-item cited-by__entry__author">D Juarez, </li><li class="list-inline-item cited-by__entry__author">RI Garza, </li><li class="list-inline-item cited-by__entry__author">H Verastiqui, </li><li class="list-inline-item cited-by__entry__author">K Wright, </li><li class="list-inline-item cited-by__entry__author">C Puckett, </li><li class="list-inline-item cited-by__entry__author">P Raskin, </li><li class="list-inline-item cited-by__entry__author">C Rhee, </li><li class="list-inline-item cited-by__entry__author">S Abraham, </li><li class="list-inline-item cited-by__entry__author">LF Jordan, </li><li class="list-inline-item cited-by__entry__author">S Sao, </li><li class="list-inline-item cited-by__entry__author">L Morton, </li><li class="list-inline-item cited-by__entry__author">O Smith, </li><li class="list-inline-item cited-by__entry__author">L Osornio Walker, </li><li class="list-inline-item cited-by__entry__author">L Schnurr-Breen, </li><li class="list-inline-item cited-by__entry__author">R Ayala, </li><li class="list-inline-item cited-by__entry__author">RB Kreymer, </li><li class="list-inline-item cited-by__entry__author">D Sturgess, </li><li class="list-inline-item cited-by__entry__author">KM Utzschneider, </li><li class="list-inline-item cited-by__entry__author">SE Kahn, </li><li class="list-inline-item cited-by__entry__author">L Alarcon-Casas Wright, </li><li class="list-inline-item cited-by__entry__author">EJ Boyko, </li><li class="list-inline-item cited-by__entry__author">EC Tsai, </li><li class="list-inline-item cited-by__entry__author">DL Trence, </li><li class="list-inline-item cited-by__entry__author">S Trikudanathan, </li><li class="list-inline-item cited-by__entry__author">BN Fattaleh, </li><li class="list-inline-item cited-by__entry__author">BK Montgomery, </li><li class="list-inline-item cited-by__entry__author">KM Atkinson, </li><li class="list-inline-item cited-by__entry__author">A Kozedub, </li><li class="list-inline-item cited-by__entry__author">T Concepcion, </li><li class="list-inline-item cited-by__entry__author">C Moak, </li><li class="list-inline-item cited-by__entry__author">N Prikhodko, </li><li class="list-inline-item cited-by__entry__author">S Rhothisen, </li><li class="list-inline-item cited-by__entry__author">TA Elasy, </li><li class="list-inline-item cited-by__entry__author">S Martin, </li><li class="list-inline-item cited-by__entry__author">L Shackelford, </li><li class="list-inline-item cited-by__entry__author">R Goidel, </li><li class="list-inline-item cited-by__entry__author">N Hinkle, </li><li class="list-inline-item cited-by__entry__author">C Lovell, </li><li class="list-inline-item cited-by__entry__author">J Myers, </li><li class="list-inline-item cited-by__entry__author">J Lipps Hogan, </li><li class="list-inline-item cited-by__entry__author">JB McGill, </li><li class="list-inline-item cited-by__entry__author">M Salam, </li><li class="list-inline-item cited-by__entry__author">T Schweiger, </li><li class="list-inline-item cited-by__entry__author">S Kissel, </li><li class="list-inline-item cited-by__entry__author">C Recklein, </li><li class="list-inline-item cited-by__entry__author">MJ Clifton, </li><li class="list-inline-item cited-by__entry__author">W Tamborlane, </li><li class="list-inline-item cited-by__entry__author">A Camp, </li><li class="list-inline-item cited-by__entry__author">B Gulanski, </li><li class="list-inline-item cited-by__entry__author">SE Inzucchi, </li><li class="list-inline-item cited-by__entry__author">K Pham, </li><li class="list-inline-item cited-by__entry__author">M Alguard, </li><li class="list-inline-item cited-by__entry__author">P Gatcomb, </li><li class="list-inline-item cited-by__entry__author">K Lessard, </li><li class="list-inline-item cited-by__entry__author">M Perez, </li><li class="list-inline-item cited-by__entry__author">L Iannone, </li><li class="list-inline-item cited-by__entry__author">E Magenheimer, </li><li class="list-inline-item cited-by__entry__author">A Montosa, </li><li class="list-inline-item cited-by__entry__author">WT Cefalu, </li><li class="list-inline-item cited-by__entry__author">J Fradkin, </li><li class="list-inline-item cited-by__entry__author">HB Burch, </li><li class="list-inline-item cited-by__entry__author">AA Bremer, </li><li class="list-inline-item cited-by__entry__author">DM Nathan, </li><li class="list-inline-item cited-by__entry__author">DM Nathan, </li><li class="list-inline-item cited-by__entry__author">JM Lachin, </li><li class="list-inline-item cited-by__entry__author">JB Buse, </li><li class="list-inline-item cited-by__entry__author">SE Kahn, </li><li class="list-inline-item cited-by__entry__author">H Krause-Steinrauf, </li><li class="list-inline-item cited-by__entry__author">ME Larkin, </li><li class="list-inline-item cited-by__entry__author">M Tiktin, </li><li class="list-inline-item cited-by__entry__author">D Wexler, </li><li class="list-inline-item cited-by__entry__author">HB Burch, </li><li class="list-inline-item cited-by__entry__author">AA Bremer, </li><li class="list-inline-item cited-by__entry__author">JM Lachin, </li><li class="list-inline-item cited-by__entry__author">H Krause-Steinrauf, </li><li class="list-inline-item cited-by__entry__author">N Younes, </li><li class="list-inline-item cited-by__entry__author">I Bebu, </li><li class="list-inline-item cited-by__entry__author">N Butera, </li><li class="list-inline-item cited-by__entry__author">CJ Buys, </li><li class="list-inline-item cited-by__entry__author">A Fagan, </li><li class="list-inline-item cited-by__entry__author">Y Gao, </li><li class="list-inline-item cited-by__entry__author">A Ghosh, </li><li class="list-inline-item cited-by__entry__author">MR Gramzinski, </li><li class="list-inline-item cited-by__entry__author">SD Hall, </li><li class="list-inline-item cited-by__entry__author">E Kazemi, </li><li class="list-inline-item cited-by__entry__author">E Legowski, </li><li class="list-inline-item cited-by__entry__author">H Liu, </li><li class="list-inline-item cited-by__entry__author">C Suratt, </li><li class="list-inline-item cited-by__entry__author">M Tripputi, </li><li class="list-inline-item cited-by__entry__author">A Arey, </li><li class="list-inline-item cited-by__entry__author">M Backman, </li><li class="list-inline-item cited-by__entry__author">J Bethepu, </li><li class="list-inline-item cited-by__entry__author">C Lund, </li><li class="list-inline-item cited-by__entry__author">P Mangat Dhaliwal, </li><li class="list-inline-item cited-by__entry__author">P McGee, </li><li class="list-inline-item cited-by__entry__author">E Mesimer, </li><li class="list-inline-item cited-by__entry__author">L Ngo, </li><li class="list-inline-item cited-by__entry__author">M Steffes, </li><li class="list-inline-item cited-by__entry__author">J Seegmiller, </li><li class="list-inline-item cited-by__entry__author">A Saenger, </li><li class="list-inline-item cited-by__entry__author">V Arends, </li><li class="list-inline-item cited-by__entry__author">D Gabrielson, </li><li class="list-inline-item cited-by__entry__author">T Conner, </li><li class="list-inline-item cited-by__entry__author">S Warren, </li><li class="list-inline-item cited-by__entry__author">J Day, </li><li class="list-inline-item cited-by__entry__author">J Huminik, </li><li class="list-inline-item cited-by__entry__author">A Scrymgeour, </li><li class="list-inline-item cited-by__entry__author">EZ Soliman, </li><li class="list-inline-item cited-by__entry__author">Y Pokharel, </li><li class="list-inline-item cited-by__entry__author">ZM Zhang, </li><li class="list-inline-item cited-by__entry__author">C Campbell, </li><li class="list-inline-item cited-by__entry__author">J Hu, </li><li class="list-inline-item cited-by__entry__author">L Keasler, </li><li class="list-inline-item cited-by__entry__author">S Hensley, </li><li class="list-inline-item cited-by__entry__author">Y Li, </li><li class="list-inline-item cited-by__entry__author">WH Herman, </li><li class="list-inline-item cited-by__entry__author">S Kuo, </li><li class="list-inline-item cited-by__entry__author">C Martin, </li><li class="list-inline-item cited-by__entry__author">A Waltje, </li><li class="list-inline-item cited-by__entry__author">R Mihalcea, </li><li class="list-inline-item cited-by__entry__author">DJ Min, </li><li class="list-inline-item cited-by__entry__author">V Perez-Rosas, </li><li class="list-inline-item cited-by__entry__author">L Prosser, </li><li class="list-inline-item cited-by__entry__author">K Resnicow, </li><li class="list-inline-item cited-by__entry__author">W Ye, </li><li class="list-inline-item cited-by__entry__author">H Shao, </li><li class="list-inline-item cited-by__entry__author">P Zhang, </li><li class="list-inline-item cited-by__entry__author">J Luchsinger, </li><li class="list-inline-item cited-by__entry__author">D Sanchez, </li><li class="list-inline-item cited-by__entry__author">S Assuras, </li><li class="list-inline-item cited-by__entry__author">E Groessl, </li><li class="list-inline-item cited-by__entry__author">F Sakha, </li><li class="list-inline-item cited-by__entry__author">H Chong, </li><li class="list-inline-item cited-by__entry__author">N Hillery, </li><li class="list-inline-item cited-by__entry__author">BM Everett, </li><li class="list-inline-item cited-by__entry__author">I Abdouch, </li><li class="list-inline-item cited-by__entry__author">G Bahtiyar, </li><li class="list-inline-item cited-by__entry__author">P Brantley, </li><li class="list-inline-item cited-by__entry__author">FE Broyles, </li><li class="list-inline-item cited-by__entry__author">G Canaris, </li><li class="list-inline-item cited-by__entry__author">P Copeland, </li><li class="list-inline-item cited-by__entry__author">JJ Craine, </li><li class="list-inline-item cited-by__entry__author">WL Fein, </li><li class="list-inline-item cited-by__entry__author">A Gliwa, </li><li class="list-inline-item cited-by__entry__author">L Hope, </li><li class="list-inline-item cited-by__entry__author">MS Lee, </li><li class="list-inline-item cited-by__entry__author">R Meiners, </li><li class="list-inline-item cited-by__entry__author">V Meiners, </li><li class="list-inline-item cited-by__entry__author">H O’Neal, </li><li class="list-inline-item cited-by__entry__author">JE Park, </li><li class="list-inline-item cited-by__entry__author">A Sacerdote, </li><li class="list-inline-item cited-by__entry__author">E Sledge, </li><li class="list-inline-item cited-by__entry__author">L Soni, </li><li class="list-inline-item cited-by__entry__author">J Steppel-Reznik, </li><li class="list-inline-item cited-by__entry__author">A Turchin, </li></ul><span class="cited-by__entry__title">Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial, </span><span class="cited-by__entry__series-title">Diabetes Care, </span><span class="cited-by__entry__volume"><strong>48</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(935-944), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.2337/dc24-2825" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.2337/dc24-2825</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.2337/dc24-2825" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Zhican Liu, </li><li class="list-inline-item cited-by__entry__author">Hailong Hu, </li><li class="list-inline-item cited-by__entry__author">Jianping Zeng, </li><li class="list-inline-item cited-by__entry__author">Mingyan Jiang, </li></ul><span class="cited-by__entry__title">Type 2 diabetes increases the risk of mortality and cardiovascular events in ischemic HFmrEF patients: a retrospective cohort study, </span><span class="cited-by__entry__series-title">Diabetology &amp; Metabolic Syndrome, </span><span class="cited-by__entry__volume"><strong>17</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s13098-025-01627-6" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s13098-025-01627-6</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s13098-025-01627-6" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Stephen Colagiuri, </li><li class="list-inline-item cited-by__entry__author">Antonio Ceriello, </li></ul><span class="cited-by__entry__title">4. Blood glucose-lowering therapies – Insulin options for type 2 diabetes, </span><span class="cited-by__entry__series-title">Diabetes Research and Clinical Practice, </span><span class="cited-by__entry__volume"><strong>222</strong>, </span><span class="cited-by__entry__page-range">(112148), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.diabres.2025.112148" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.diabres.2025.112148</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.diabres.2025.112148" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Amedeo Lonardo, </li><li class="list-inline-item cited-by__entry__author">Ashwani K. Singal, </li></ul><span class="cited-by__entry__title">Duodenal mucosa resurfacing: the endoscopic silver bullet against metabolic disorders?, </span><span class="cited-by__entry__series-title">Metabolism and Target Organ Damage, </span><span class="cited-by__entry__volume"><strong>5</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.20517/mtod.2024.130" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.20517/mtod.2024.130</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.20517/mtod.2024.130" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yan Lin, </li><li class="list-inline-item cited-by__entry__author">Chunyan Yi, </li><li class="list-inline-item cited-by__entry__author">Peiyi Cao, </li><li class="list-inline-item cited-by__entry__author">Jianxiong Lin, </li><li class="list-inline-item cited-by__entry__author">Wei Chen, </li><li class="list-inline-item cited-by__entry__author">Haiping Mao, </li><li class="list-inline-item cited-by__entry__author">Xiao Yang, </li><li class="list-inline-item cited-by__entry__author">Qunying Guo, </li></ul><span class="cited-by__entry__title">Visit-to-visit blood pressure variability and clinical outcomes in peritoneal dialysis – based on machine learning algorithms, </span><span class="cited-by__entry__series-title">Hypertension Research, </span><span class="cited-by__entry__volume"><strong>48</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(1702-1715), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41440-025-02142-x" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41440-025-02142-x</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41440-025-02142-x" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Patrizia Natale, </li><li class="list-inline-item cited-by__entry__author">Suetonia C Green, </li><li class="list-inline-item cited-by__entry__author">David J Tunnicliffe, </li><li class="list-inline-item cited-by__entry__author">Giovanni Pellegrino, </li><li class="list-inline-item cited-by__entry__author">Tadashi Toyama, </li><li class="list-inline-item cited-by__entry__author">Giovanni FM Strippoli, </li></ul><span class="cited-by__entry__title">Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes, </span><span class="cited-by__entry__series-title">Cochrane Database of Systematic Reviews, </span><span class="cited-by__entry__volume"><strong>2025</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/14651858.CD015849.pub2" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/14651858.CD015849.pub2</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/14651858.CD015849.pub2" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Zhengwen Xu, </li><li class="list-inline-item cited-by__entry__author">Xisheng Yan, </li><li class="list-inline-item cited-by__entry__author">Dongsheng Li, </li><li class="list-inline-item cited-by__entry__author">Xiaodong Huang, </li></ul><span class="cited-by__entry__title">Triglyceride glucose index as a biomarker for heart failure risk in H-type hypertension patients, </span><span class="cited-by__entry__series-title">Scientific Reports, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41598-025-89211-w" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41598-025-89211-w</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41598-025-89211-w" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2200436%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-12%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2200436" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2200436" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2200436.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200436_f1.jpg"><img src="/cms/10.1056/NEJMoa2200436/asset/8520e487-5c63-4fe0-bca8-d216ceacc1b6/assets/images/large/nejmoa2200436_f1.jpg" height="1185" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Cumulative Incidences of Hypertension and Dyslipidemia in the Intention-to-Treat Analyses.</div><div class="notes"><div role="doc-footnote">Shown are the cumulative incidences of hypertension (Panel A) and dyslipidemia (Panel B) over 6.5 years of follow-up among participants who did not have each condition at baseline. The numbers plotted below the x axis of each panel are the numbers of participants at risk for the outcome at each follow-up time point (i.e., the number of participants in whom a specified outcome event had not developed by that time). Participants who had the condition at baseline were excluded, leaving 1168 of 5047 participants (23%) in the analysis of hypertension and 195 of 5047 participants (4%) in the analysis of dyslipidemia. There was no substantial difference among the groups with respect to the cumulative incidences of hypertension or dyslipidemia.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200436_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200436_f2.jpg"><img src="/cms/10.1056/NEJMoa2200436/asset/30af31dc-345b-4104-a222-d2b019323c27/assets/images/large/nejmoa2200436_f2.jpg" height="2248" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Cumulative Incidences of Microvascular Outcomes in the Intention-to-Treat Analyses.</div><div class="notes"><div role="doc-footnote">Shown are the cumulative incidences of the following conditions over 6.5 years of follow-up among participants who did not have one of these conditions at baseline: confirmed moderately increased albuminuria level (≥30 mg of albumin per gram of creatinine) or dialysis, transplantation, or death due to end-stage kidney disease (Panel A); severely increased albuminuria level (≥300 mg of albumin per gram of creatinine) or dialysis, transplantation, or death due to end-stage kidney disease (Panel B); renal impairment (estimated glomerular filtration rate of &lt;60 ml per minute per 1.73 m<sup>2</sup> of body-surface area) (Panel C); and diabetic peripheral neuropathy (Panel D). The numbers plotted below the x axis of each panel are the participants at risk for the outcome at each follow-up time point (i.e., the number of participants in whom a specified outcome event had not developed by that time). The insets show the same data on an enlarged y axis.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200436_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f3"><figure class="graphic"><a class="open-in-viewer" href="#f3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200436_f3.jpg"><img src="/cms/10.1056/NEJMoa2200436/asset/1ba49ff9-e36b-4fba-a94e-e53a181c5476/assets/images/large/nejmoa2200436_f3.jpg" height="3343" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Cumulative Incidences of Cardiovascular Outcomes and Mortality in the Intention-to-Treat Analyses.</div><div class="notes"><div role="doc-footnote">Shown are the cumulative incidences of any cardiovascular disease (Panel A), a major adverse cardiovascular event (MACE) (Panel B), hospitalization for heart failure (Panel C), death from cardiovascular causes (Panel D), and death from any cause (Panel E) over 6.5 years of follow-up. The numbers plotted below the x axis of each panel are the participants at risk for the outcome at each follow-up time point (i.e., the number of participants in whom a specified outcome event had not developed by that time).</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f3"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200436_f3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200436_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2200436/asset/7dae3cf4-6282-4c0e-acf5-33d81a528abb/assets/images/large/nejmoa2200436_t1.jpg" height="3307" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">Glargine<br>(N=1263)</th><th class="txxx-borders">Glimepiride<br>(N=1254)</th><th class="txxx-borders">Liraglutide<br>(N=1262)</th><th class="txxx-borders">Sitagliptin<br>(N=1268)</th><th class="txxr-borders">Total<br>(N=5047)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Moderately increased albuminuria level<a href="#core-t1fn2" role="doc-noteref">†</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders">136/1066 (12.8)</td><td class="xxxx-borders">135/1046 (12.9)</td><td class="xxxx-borders">121/1040 (11.6)</td><td class="xxxx-borders">115/1070 (10.7)</td><td class="xxxr-borders">507/4222 (12.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Rate (95% CI) — events/100 participant-yr</td><td class="xxxx-borders shading">2.76 (2.32–3.26)</td><td class="xxxx-borders shading">2.78 (2.33–3.29)</td><td class="xxxx-borders shading">2.46 (2.05–2.95)</td><td class="xxxx-borders shading">2.30 (1.90–2.76)</td><td class="xxxr-borders shading">2.57 (2.35–2.81)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glargine</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1.00 (0.78–1.26)</td><td class="xxxx-borders shading">1.12 (0.88–1.43)</td><td class="xxxx-borders shading">1.20 (0.94–1.54)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glimepiride</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1.12 (0.88–1.44)</td><td class="xxxx-borders">1.21 (0.94–1.55)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Liraglutide</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" data-xml-align="center">1.07 (0.83–1.39)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Sitagliptin</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xxxx-borders shading">1.10 (0.91–1.34)</td><td class="xxxx-borders shading">1.11 (0.91–1.35)</td><td class="xxxx-borders shading">0.95 (0.77–1.16)</td><td class="xxxx-borders shading">0.86 (0.70–1.06)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Severely increased albuminuria level<a href="#core-t1fn3" role="doc-noteref">‡</a></b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders shading">59/1240 (4.8)</td><td class="xxxx-borders shading">64/1220 (5.2)</td><td class="xxxx-borders shading">70/1229 (5.7)</td><td class="xxxx-borders shading">66/1246 (5.3)</td><td class="xxxr-borders shading">259/4935 (5.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Rate (95% CI) — events/100 participant-yr</td><td class="xxxx-borders">0.97 (0.74–1.26)</td><td class="xxxx-borders">1.08 (0.83–1.38)</td><td class="xxxx-borders">1.17 (0.91–1.48)</td><td class="xxxx-borders">1.09 (0.85–1.39)</td><td class="xxxr-borders">1.08 (0.95–1.22)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glargine</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.90 (0.63–1.28)</td><td class="xxxx-borders">0.83 (0.59–1.18)</td><td class="xxxx-borders">0.89 (0.63–1.26)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glimepiride</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.92 (0.66–1.29)</td><td class="xxxx-borders shading">0.99 (0.70–1.39)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Liraglutide</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders" data-xml-align="center">1.07 (0.76–1.50)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Sitagliptin</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xxxx-borders">0.87 (0.65–1.17)</td><td class="xxxx-borders">1.00 (0.76–1.33)</td><td class="xxxx-borders">1.12 (0.85–1.47)</td><td class="xxxx-borders">1.02 (0.77–1.35)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Renal impairment<a href="#core-t1fn4" role="doc-noteref">§</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders">144/1174 (12.3)</td><td class="xxxx-borders">151/1198 (12.6)</td><td class="xxxx-borders">170/1184 (14.4)</td><td class="xxxx-borders">145/1208 (12.0)</td><td class="xxxr-borders">610/4764 (12.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Rate (95% CI) — events/100 participant-yr</td><td class="xxxx-borders shading">2.78 (2.35–3.28)</td><td class="xxxx-borders shading">2.88 (2.44–3.38)</td><td class="xxxx-borders shading">3.26 (2.79–3.78)</td><td class="xxxx-borders shading">2.73 (2.31–3.22)</td><td class="xxxr-borders shading">2.91 (2.69–3.15)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glargine</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.96 (0.76–1.20)</td><td class="xxxx-borders shading">0.85 (0.69–1.07)</td><td class="xxxx-borders shading">1.02 (0.81–1.28)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glimepiride</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.89 (0.72–1.11)</td><td class="xxxx-borders">1.07 (0.85–1.34)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Liraglutide</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" data-xml-align="center">1.19 (0.95–1.49)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Sitagliptin</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xxxx-borders shading">0.94 (0.78–1.13)</td><td class="xxxx-borders shading">1.00 (0.83–1.20)</td><td class="xxxx-borders shading">1.16 (0.97–1.38)</td><td class="xxxx-borders shading">0.92 (0.76–1.11)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Diabetic peripheral</b> <b>neuropathy</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders shading">393/751 (52.3)</td><td class="xxxx-borders shading">427/728 (58.7)</td><td class="xxxx-borders shading">382/704 (54.3)</td><td class="xxxx-borders shading">405/723 (56.0)</td><td class="xxxr-borders shading">1607/2906 (55.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Rate (95% CI) — events/100 participant-yr</td><td class="xxxx-borders">15.57 (14.07–17.19)</td><td class="xxxx-borders">18.22 (16.53–20.04)</td><td class="xxxx-borders">16.06 (14.49–17.75)</td><td class="xxxx-borders">16.87 (15.27–18.60)</td><td class="xxxr-borders">16.66 (15.85–17.49)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glargine</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.85 (0.74–0.97)</td><td class="xxxx-borders">0.96 (0.84–1.11)</td><td class="xxxx-borders">0.92 (0.80–1.06)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glimepiride</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1.14 (0.99–1.31)</td><td class="xxxx-borders shading">1.08 (0.95–1.24)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Liraglutide</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders" data-xml-align="center">0.95 (0.83–1.10)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Sitagliptin</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xbxx-borders">0.91 (0.81–1.02)</td><td class="xbxx-borders">1.13 (1.01–1.27)</td><td class="xbxx-borders">0.96 (0.85–1.07)</td><td class="xbxx-borders">1.02 (0.91–1.14)</td><td class="xbxr-borders">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">The number of participants at risk excludes the prevalent cases at baseline that were not counted in either the numerator or denominator of the calculation of the rate. Pairwise hazard ratios were calculated from an analysis of the differences in the hazards among any of the four treatment groups, on the basis of a Cox proportional-hazards model, with treatment group as the only predictor variable. The 95% confidence intervals (CIs) were not corrected for multiple comparisons.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">A moderately increased albuminuria level was defined as a confirmed urinary albumin:creatinine ratio of at least 30, as measured in milligrams of albumin to grams of creatinine.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">A severely increased albuminuria level was defined as a urinary albumin:creatinine ratio of at least 300, as measured in milligrams of albumin to grams of creatinine.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Impaired renal function was defined as an estimated glomerular filtration rate of less than 60 ml per minute per 1.73 m<sup>2</sup>. Participants in whom incident end-stage kidney disease (as defined by dialysis, transplantation, or death from kidney disease) developed during the trial were considered to have had an outcome event in the categories of albuminuria (moderately increased albuminuria and severely increased albuminuria) and renal impairment.</div></div></div></figcaption></a><figcaption><div class="caption">Microvascular Outcomes in the Intention-to-Treat Analysis.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200436_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200436_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2200436/asset/7008d4df-93a9-4998-a55b-03c77c67ad6c/assets/images/large/nejmoa2200436_t2.jpg" height="3438" width="1970" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">Glargine<br>(N=1263)</th><th class="txxx-borders">Glimepiride<br>(N=1254)</th><th class="txxx-borders">Liraglutide<br>(N=1262)</th><th class="txxx-borders">Sitagliptin<br>(N=1268)</th><th class="txxr-borders">Total<br>(N=5047)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Any cardiovascular disease<a href="#core-t2fn2" role="doc-noteref">†</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders">113/1257 (9.0)</td><td class="xxxx-borders">115/1247 (9.2)</td><td class="xxxx-borders">83/1251 (6.6)</td><td class="xxxx-borders">121/1264 (9.6)</td><td class="xxxr-borders">432/5019 (8.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Rate (95% CI)</td><td class="xxxx-borders shading">1.87 (1.54–2.25)</td><td class="xxxx-borders shading">1.92 (1.59–2.31)</td><td class="xxxx-borders shading">1.36 (1.08–1.69)</td><td class="xxxx-borders shading">2.00 (1.66–2.39)</td><td class="xxxr-borders shading">1.79 (1.62–1.96)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glargine</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.97 (0.75–1.26)</td><td class="xxxx-borders shading">1.37 (1.03–1.82)</td><td class="xxxx-borders shading">0.93 (0.72–1.21)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glimepiride</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1.41 (1.07–1.87)</td><td class="xxxx-borders">0.96 (0.74–1.24)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Liraglutide</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" data-xml-align="center">0.68 (0.51–0.90)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Sitagliptin</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xxxx-borders shading">1.07 (0.87–1.33)</td><td class="xxxx-borders shading">1.12 (0.90–1.39)</td><td class="xxxx-borders shading">0.71 (0.56–0.90)</td><td class="xxxx-borders shading">1.18 (0.96–1.46)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>MACE</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders shading">65/1257 (5.2)</td><td class="xxxx-borders shading">59/1247 (4.7)</td><td class="xxxx-borders shading">48/1251 (3.8)</td><td class="xxxx-borders shading">69/1264 (5.5)</td><td class="xxxr-borders shading">241/5019 (4.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Rate (95% CI)</td><td class="xxxx-borders">1.05 (0.81–1.34)</td><td class="xxxx-borders">0.96 (0.73–1.24)</td><td class="xxxx-borders">0.78 (0.57–1.03)</td><td class="xxxx-borders">1.12 (0.87–1.41)</td><td class="xxxr-borders">0.98 (0.86–1.11)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glargine</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1.09 (0.77–1.55)</td><td class="xxxx-borders">1.35 (0.93–1.96)</td><td class="xxxx-borders">0.94 (0.67–1.32)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glimepiride</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1.24 (0.85–1.81)</td><td class="xxxx-borders shading">0.86 (0.61–1.22)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Liraglutide</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders" data-xml-align="center">0.70 (0.48–1.01)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Sitagliptin</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xxxx-borders">1.12 (0.84–1.49)</td><td class="xxxx-borders">0.99 (0.74–1.33)</td><td class="xxxx-borders">0.75 (0.54–1.03)</td><td class="xxxx-borders">1.21 (0.91–1.60)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Hospitalization for heart failure</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders">26/1257 (2.1)</td><td class="xxxx-borders">30/1247 (2.4)</td><td class="xxxx-borders">14/1251 (1.1)</td><td class="xxxx-borders">30/1264 (2.4)</td><td class="xxxr-borders">100/5019 (2.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Rate (95% CI)</td><td class="xxxx-borders shading">0.42 (0.27–0.61)</td><td class="xxxx-borders shading">0.48 (0.33–0.69)</td><td class="xxxx-borders shading">0.22 (0.12–0.38)</td><td class="xxxx-borders shading">0.48 (0.32–0.68)</td><td class="xxxr-borders shading">0.40 (0.33–0.49)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glargine</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.86 (0.51–1.45)</td><td class="xxxx-borders shading">1.85 (0.96–3.55)</td><td class="xxxx-borders shading">0.87 (0.51–1.47)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glimepiride</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2.16 (1.14–4.06)</td><td class="xxxx-borders">1.01 (0.61–1.67)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Liraglutide</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" data-xml-align="center">0.47 (0.25–0.88)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Sitagliptin</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xxxx-borders shading">1.11 (0.70–1.76)</td><td class="xxxx-borders shading">1.36 (0.88–2.11)</td><td class="xxxx-borders shading">0.49 (0.28–0.86)</td><td class="xxxx-borders shading">1.35 (0.87–2.08)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Death from cardiovascular causes</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders shading">21/1257 (1.7)</td><td class="xxxx-borders shading">16/1247 (1.3)</td><td class="xxxx-borders shading">9/1251 (0.7)</td><td class="xxxx-borders shading">21/1264 (1.7)</td><td class="xxxr-borders shading">67/5019 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Rate (95% CI)</td><td class="xxxx-borders">0.33 (0.21–0.51)</td><td class="xxxx-borders">0.26 (0.15–0.42)</td><td class="xxxx-borders">0.14 (0.07–0.27)</td><td class="xxxx-borders">0.33 (0.21–0.51)</td><td class="xxxr-borders">0.27 (0.21–0.34)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glargine</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1.29 (0.67–2.47)</td><td class="xxxx-borders">2.30 (1.05–5.01)</td><td class="xxxx-borders">1.00 (0.55–1.82)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glimepiride</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1.78 (0.79–4.04)</td><td class="xxxx-borders shading">0.77 (0.40–1.48)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Liraglutide</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders" data-xml-align="center">0.43 (0.20–0.95)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Sitagliptin</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xxxx-borders">1.43 (0.85–2.43)</td><td class="xxxx-borders">1.02 (0.58–1.82)</td><td class="xxxx-borders">0.47 (0.23–0.95)</td><td class="xxxx-borders">1.44 (0.85–2.44)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Death from any cause</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of participants/no. at risk (%)</td><td class="xxxx-borders">42/1263 (3.3)</td><td class="xxxx-borders">43/1254 (3.4)</td><td class="xxxx-borders">27/1262 (2.1)</td><td class="xxxx-borders">41/1267 (3.2)</td><td class="xxxr-borders">153/5046 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Rate (95% CI)</td><td class="xxxx-borders shading">0.65 (0.47–0.87)</td><td class="xxxx-borders shading">0.67 (0.48–0.90)</td><td class="xxxx-borders shading">0.42 (0.27–0.60)</td><td class="xxxx-borders shading">0.63 (0.45–0.86)</td><td class="xxxr-borders shading">0.59 (0.50–0.69)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Pairwise hazard ratio (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glargine</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.96 (0.63–1.46)</td><td class="xxxx-borders shading">1.54 (0.95–2.50)</td><td class="xxxx-borders shading">1.02 (0.66–1.57)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Glimepiride</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1.61 (1.00–2.61)</td><td class="xxxx-borders">1.07 (0.69–1.63)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Liraglutide</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading" data-xml-align="center">0.66 (0.41–1.07)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Sitagliptin</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Hazard ratio (95% CI) in one agent as compared with the others combined</td><td class="xbxx-borders shading">1.15 (0.80–1.64)</td><td class="xbxx-borders shading">1.22 (0.85–1.73)</td><td class="xbxx-borders shading">0.64 (0.42–0.97)</td><td class="xbxx-borders shading">1.12 (0.78–1.60)</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">The number of participants at risk excludes the prevalent cases at baseline that were not counted in either the numerator or the denominator of the calculation of the rate. Pairwise hazard ratios were calculated from an analysis of the differences in the hazards among any of the four treatment groups, on the basis of a Cox proportional-hazards model, with treatment group as the only predictor variable. The 95% confidence intervals were not corrected for multiple comparisons.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Any cardiovascular disease was defined as the first of any major adverse cardiovascular event (MACE; defined as death from cardiovascular disease or nonfatal myocardial infarction or stroke), unstable angina warranting hospitalization or revascularization, heart failure warranting hospitalization, or any revascularization event.</div></div></div></figcaption></a><figcaption><div class="caption">Cardiovascular and Mortality Outcomes in the Intention-to-Treat Analysis.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2200436_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2200436</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. <em>Diabetes Care</em> 2018;41:917-928.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dci18-0007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29567642/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000430456100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Economic+costs+of+diabetes+in+the+U.S.+in+2017.&amp;publication_year=2018&amp;journal=Diabetes+Care&amp;pages=917-928&amp;doi=10.2337%2Fdci18-0007&amp;pmid=29567642" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). <em>Lancet</em> 1998;352:837-853.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(98)07019-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9742976/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000075857300006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intensive+blood-glucose+control+with+sulphonylureas+or+insulin+compared+with+conventional+treatment+and+risk+of+complications+in+patients+with+type+2+diabetes+%28UKPDS+33%29.&amp;publication_year=1998&amp;journal=Lancet&amp;pages=837-853&amp;doi=10.1016%2FS0140-6736%2898%2907019-6&amp;pmid=9742976" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] microvascular complications. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] factors for microvascular complications, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. <em>Cochrane Database Syst Rev</em> 2013;11:CD008143-CD008143.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24214280/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000327587700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+intensive+glycaemic+control+versus+targeting+conventional+glycaemic+control+for+type+2+diabetes+mellitus.&amp;publication_year=2013&amp;journal=Cochrane+Database+Syst+Rev&amp;pages=CD008143-CD008143&amp;pmid=24214280" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. <em>N Engl J Med</em> 2016;375:311-322.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_5_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200436&amp;key=10.1056%2FNEJMoa1603827&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27295427/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000380313200005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Liraglutide+and+cardiovascular+outcomes+in+type+2+diabetes.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=311-322&amp;doi=10.1056%2FNEJMoa1603827&amp;pmid=27295427" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in participants with preexisting disease, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] than the population in the current trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] than the population in the current trial. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. <em>N Engl J Med</em> 2015;373:2117-2128.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_6_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200436&amp;key=10.1056%2FNEJMoa1504720&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26378978/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365354800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Empagliflozin%2C+cardiovascular+outcomes%2C+and+mortality+in+type+2+diabetes.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=2117-2128&amp;doi=10.1056%2FNEJMoa1504720&amp;pmid=26378978" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. <em>N Engl J Med</em> 2017;377:644-657.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200436&amp;key=10.1056%2FNEJMoa1611925&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28605608/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407691400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Canagliflozin+and+cardiovascular+and+renal+events+in+type+2+diabetes.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=644-657&amp;doi=10.1056%2FNEJMoa1611925&amp;pmid=28605608" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in participants with preexisting disease, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] or potentially harmful side effects. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. <em>N Engl J Med</em> 2015;373:232-242.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_8_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200436&amp;key=10.1056%2FNEJMoa1501352&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26052984/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000357956200006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+sitagliptin+on+cardiovascular+outcomes+in+type+2+diabetes.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=232-242&amp;doi=10.1056%2FNEJMoa1501352&amp;pmid=26052984" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. <em>Lancet</em> 2005;366:1279-1289.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(05)67528-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16214598/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000232405700026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Secondary+prevention+of+macrovascular+events+in+patients+with+type+2+diabetes+in+the+PROactive+study+%28PROspective+pioglitAzone+Clinical+Trial+In+macroVascular+Events%29%3A+a+randomised+controlled+trial.&amp;publication_year=2005&amp;journal=Lancet&amp;pages=1279-1289&amp;doi=10.1016%2FS0140-6736%2805%2967528-9&amp;pmid=16214598" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. <em>N Engl J Med</em> 2016;375:1834-1844.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_10_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200436&amp;key=10.1056%2FNEJMoa1607141&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27633186/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387534200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Semaglutide+and+cardiovascular+outcomes+in+patients+with+type+2+diabetes.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=1834-1844&amp;doi=10.1056%2FNEJMoa1607141&amp;pmid=27633186" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] or potentially harmful side effects. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] than the population in the current trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] than the population in the current trial. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). <em>Diabetes Care</em> 2013;36:2254-2261.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc13-0356" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23690531/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000327252600038" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rationale+and+design+of+the+glycemia+reduction+approaches+in+diabetes%3A+a+comparative+effectiveness+study+%28GRADE%29.&amp;publication_year=2013&amp;journal=Diabetes+Care&amp;pages=2254-2261&amp;doi=10.2337%2Fdc13-0356&amp;pmid=23690531" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] type 2 diabetes mellitus of recent onset. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] labeling, in combination with metformin. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">GRADE Study Research Group. Glycemia reduction in type 2 diabetes — glycemic outcomes. <em>N Engl J Med</em> 2022;387:1067-1074.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000865461700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glycemia+reduction+in+type+2+diabetes+%E2%80%94+glycemic+outcomes.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=1067-1074" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Journal. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] is provided in the companion article. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in detail in the accompanying article. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] those described in the companion article. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] group and 7.3% in the glimepiride group. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] targeted glycated hemoglobin levels. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] including the small separation in glycemia, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Wexler DJ, Krause-Steinrauf H, Crandall JP, et al. Baseline characteristics of randomized participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <em>Diabetes Care</em> 2019;42:2098-2107.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dc19-0901" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31391203/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491450200017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Baseline+characteristics+of+randomized+participants+in+the+Glycemia+Reduction+Approaches+in+Diabetes%3A+A+Comparative+Effectiveness+Study+%28GRADE%29.&amp;publication_year=2019&amp;journal=Diabetes+Care&amp;pages=2098-2107&amp;doi=10.2337%2Fdc19-0901&amp;pmid=31391203" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have been published previously. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] trial cohort have been reported previously, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] medical centers as trial recruitment sites. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <em>Diabetes Care</em> 2018;41:2669-2701.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dci18-0033" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30291106/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450560000037" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Management+of+hyperglycemia+in+type+2+diabetes%2C+2018%3A+a+consensus+report+by+the+American+Diabetes+Association+%28ADA%29+and+the+European+Association+for+the+Study+of+Diabetes+%28EASD%29.&amp;publication_year=2018&amp;journal=Diabetes+Care&amp;pages=2669-2701&amp;doi=10.2337%2Fdci18-0033&amp;pmid=30291106" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <em>Diabetes Care</em> 2020;43:487-493.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/dci19-0066" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31857443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000508199900043" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2019+Update+to%3A+management+of+hyperglycemia+in+type+2+diabetes%2C+2018%3A+a+consensus+report+by+the+American+Diabetes+Association+%28ADA%29+and+the+European+Association+for+the+Study+of+Diabetes+%28EASD%29.&amp;publication_year=2020&amp;journal=Diabetes+Care&amp;pages=487-493&amp;doi=10.2337%2Fdci19-0066&amp;pmid=31857443" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. <em>N Engl J Med</em> 2012;367:20-29.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_16_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2200436&amp;key=10.1056%2FNEJMoa1114248&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22762315/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000305979400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Estimating+glomerular+filtration+rate+from+serum+creatinine+and+cystatin+C.&amp;publication_year=2012&amp;journal=N+Engl+J+Med&amp;pages=20-29&amp;doi=10.1056%2FNEJMoa1114248&amp;pmid=22762315" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. <em>Diabetes Care</em> 1994;17:1281-1289.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2337/diacare.17.11.1281" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7821168/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994PN84300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+practical+two-step+quantitative+clinical+and+electrophysiological+assessment+for+the+diagnosis+and+staging+of+diabetic+neuropathy.&amp;publication_year=1994&amp;journal=Diabetes+Care&amp;pages=1281-1289&amp;doi=10.2337%2Fdiacare.17.11.1281&amp;pmid=7821168" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and vibration sensation at the great toes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of 2.5 or higher, as previously described. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Hicks KA, Mahaffey KW, Mehran R, et al. 2017 Cardiovascular and stroke endpoint definitions for clinical trials. <em>Circulation</em> 2018;137:961-972.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/CIRCULATIONAHA.117.033502" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29483172/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000426206800011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2017+Cardiovascular+and+stroke+endpoint+definitions+for+clinical+trials.&amp;publication_year=2018&amp;journal=Circulation&amp;pages=961-972&amp;doi=10.1161%2FCIRCULATIONAHA.117.033502&amp;pmid=29483172" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Mather KJ, Bebu I, Baker C, et al. Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes — A Comparative Effectiveness (GRADE) study cohort. <em>Diabetes Res Clin Pract</em> 2020;165:108235-108235.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.diabres.2020.108235" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32450102/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000554922700015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prevalence+of+microvascular+and+macrovascular+disease+in+the+Glycemia+Reduction+Approaches+in+Diabetes+%E2%80%94+A+Comparative+Effectiveness+%28GRADE%29+study+cohort.&amp;publication_year=2020&amp;journal=Diabetes+Res+Clin+Pract&amp;pages=108235-108235&amp;doi=10.1016%2Fj.diabres.2020.108235&amp;pmid=32450102" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Sarafidis PA, Bakris GL. The antinatriuretic effect of insulin: an unappreciated mechanism for hypertension associated with insulin resistance? <em>Am J Nephrol</em> 2007;27:44-54.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1159/000098955" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17245074/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000244256400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+antinatriuretic+effect+of+insulin%3A+an+unappreciated+mechanism+for+hypertension+associated+with+insulin+resistance%3F&amp;publication_year=2007&amp;journal=Am+J+Nephrol&amp;pages=44-54&amp;doi=10.1159%2F000098955&amp;pmid=17245074" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. <em>BMJ</em> 1998;317:713-720.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/bmj.317.7160.713" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9732338/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000075995100019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+atenolol+and+captopril+in+reducing+risk+of+macrovascular+and+microvascular+complications+in+type+2+diabetes%3A+UKPDS+39.&amp;publication_year=1998&amp;journal=BMJ&amp;pages=713-720&amp;doi=10.1136%2Fbmj.317.7160.713&amp;pmid=9732338" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Nathan DM, Bennett PH, Crandall JP, et al. Does diabetes prevention translate into reduced long-term vascular complications of diabetes? <em>Diabetologia</em> 2019;62:1319-1328.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00125-019-4928-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31270584/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000475698900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Does+diabetes+prevention+translate+into+reduced+long-term+vascular+complications+of+diabetes%3F&amp;publication_year=2019&amp;journal=Diabetologia&amp;pages=1319-1328&amp;doi=10.1007%2Fs00125-019-4928-8&amp;pmid=31270584" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Zoungas S, Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. <em>Diabetologia</em> 2012;55:636-643.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00125-011-2404-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22186981/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000299921200013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+of+HbA1c+levels+with+vascular+complications+and+death+in+patients+with+type+2+diabetes%3A+evidence+of+glycaemic+thresholds.&amp;publication_year=2012&amp;journal=Diabetologia&amp;pages=636-643&amp;doi=10.1007%2Fs00125-011-2404-1&amp;pmid=22186981" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <em>Lancet</em> 2019;394:121-130.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(19)31149-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31189511/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000475393900025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dulaglutide+and+cardiovascular+outcomes+in+type+2+diabetes+%28REWIND%29%3A+a+double-blind%2C+randomised+placebo-controlled+trial.&amp;publication_year=2019&amp;journal=Lancet&amp;pages=121-130&amp;doi=10.1016%2FS0140-6736%2819%2931149-3&amp;pmid=31189511" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] than the population in the current trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] than the population in the current trial. </span></a></li></ul></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 21, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2210531" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">After Metformin — Next Steps for Type 2 Diabetes with Low Cardiovascular Risk</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">L. Rydén and E. Standl</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 21, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2200433" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">The GRADE Study Research Group</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Connecticut</span></div><div><span>Physical Medicine &amp; Rehabilitation</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/893602/physiatrist-inpatient/?query=fjwp&amp;rid=165114">Physiatrist - Inpatient</a></div></div><div class="nejm-widget_item"><div><span> Tucson, Arizona</span></div><div><span>Radiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885683/abdominal-imaging-with-university-of-arizona-/?query=fjwp&amp;rid=120">Abdominal Imaging with University of Arizona!</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/882279/physician-family-medicine/?query=fjwf&amp;rid=385607">Physician - Family Medicine</a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/785012/obgyn-gynecologic-oncologist-eastern-region-long-island-ny-/?query=fjwp&amp;rid=3059">OBGYN - Gynecologic Oncologist - Eastern Region - (Long Island, NY)</a></div></div><div class="nejm-widget_item"><div><span> Loma Linda, California</span></div><div><span>Surgery, Neurological</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/884045/academic-neurosurgeon-spine-opportunity-in-southern-california/?query=fjwp&amp;rid=69418">Academic Neurosurgeon - Spine Opportunity in Southern California</a></div></div><div class="nejm-widget_item"><div><span> Henderson, Nevada</span></div><div><span>Neonatal / Perinatal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880183/neonatologist-per-diem-/?query=fjwf&amp;rid=49812">Neonatologist (Per Diem)</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2200436&amp;pubId=41284272&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6eb03277a01a6-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6eb03277a01a6-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6eb03277a01a6-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$270893393$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$270893393$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$270893393$--></div></div><div class="mlt-body"><!--?lit$270893393$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$270893393$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$270893393$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$270893393$-->Mar 27, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2412006?query=recirc_Semantic" target="_self">Intensive Blood-Pressure Control in Patients with Type 2 Diabetes</a></div><div class="mlt-article-authors"><!--?lit$270893393$-->Y. Bi and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/review-article" target="_self"><!--?lit$270893393$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$270893393$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$270893393$-->Apr 04, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMra2311526?query=recirc_Semantic" target="_self">Prevention of Cardiovascular Disease in Type 1 Diabetes</a></div><div class="mlt-article-authors"><!--?lit$270893393$-->C. Manrique-Acevedo, I.B. Hirsch, and R.H. Eckel</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/clinical-practice" target="_self"><!--?lit$270893393$-->Clinical Practice</a> <span class="mlt-article-site-label"><!--?lit$270893393$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$270893393$-->Jul 20, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMcp2102062?query=recirc_Semantic" target="_self">Obesity in Adolescents</a></div><div class="mlt-article-authors"><!--?lit$270893393$-->T.S. Hannon and S.A. Arslanian</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$270893393$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$270893393$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$270893393$-->Aug 12, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2107340?query=recirc_Semantic" target="_self">Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes</a></div><div class="mlt-article-authors"><!--?lit$270893393$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/clinical-implications-of-basic-research" target="_self"><!--?lit$270893393$-->Clinical Implications of Basic Research</a> <span class="mlt-article-site-label"><!--?lit$270893393$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$270893393$-->Feb 06, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMcibr2409089?query=recirc_Semantic" target="_self">Discovery of GLP-1–Based Drugs for the Treatment of Obesity</a></div><div class="mlt-article-authors"><!--?lit$270893393$-->D.J. Drucker</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2200436?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2200436" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2200436.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2200436"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2200433" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2206286" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200436_f1.jpg"><img src="/cms/10.1056/NEJMoa2200436/asset/8520e487-5c63-4fe0-bca8-d216ceacc1b6/assets/images/large/nejmoa2200436_f1.jpg" height="1185" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Cumulative Incidences of Hypertension and Dyslipidemia in the Intention-to-Treat Analyses.</div><div class="notes"><div role="doc-footnote">Shown are the cumulative incidences of hypertension (Panel A) and dyslipidemia (Panel B) over 6.5 years of follow-up among participants who did not have each condition at baseline. The numbers plotted below the x axis of each panel are the numbers of participants at risk for the outcome at each follow-up time point (i.e., the number of participants in whom a specified outcome event had not developed by that time). Participants who had the condition at baseline were excluded, leaving 1168 of 5047 participants (23%) in the analysis of hypertension and 195 of 5047 participants (4%) in the analysis of dyslipidemia. There was no substantial difference among the groups with respect to the cumulative incidences of hypertension or dyslipidemia.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200436_f2.jpg"><img src="/cms/10.1056/NEJMoa2200436/asset/30af31dc-345b-4104-a222-d2b019323c27/assets/images/large/nejmoa2200436_f2.jpg" height="2248" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Cumulative Incidences of Microvascular Outcomes in the Intention-to-Treat Analyses.</div><div class="notes"><div role="doc-footnote">Shown are the cumulative incidences of the following conditions over 6.5 years of follow-up among participants who did not have one of these conditions at baseline: confirmed moderately increased albuminuria level (≥30 mg of albumin per gram of creatinine) or dialysis, transplantation, or death due to end-stage kidney disease (Panel A); severely increased albuminuria level (≥300 mg of albumin per gram of creatinine) or dialysis, transplantation, or death due to end-stage kidney disease (Panel B); renal impairment (estimated glomerular filtration rate of &lt;60 ml per minute per 1.73 m<sup>2</sup> of body-surface area) (Panel C); and diabetic peripheral neuropathy (Panel D). The numbers plotted below the x axis of each panel are the participants at risk for the outcome at each follow-up time point (i.e., the number of participants in whom a specified outcome event had not developed by that time). The insets show the same data on an enlarged y axis.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f3" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2200436_f3.jpg"><img src="/cms/10.1056/NEJMoa2200436/asset/1ba49ff9-e36b-4fba-a94e-e53a181c5476/assets/images/large/nejmoa2200436_f3.jpg" height="3343" width="2640" aria-labelledby="f3" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 3</div><div class="fv__item__description"><figcaption><div class="caption">Cumulative Incidences of Cardiovascular Outcomes and Mortality in the Intention-to-Treat Analyses.</div><div class="notes"><div role="doc-footnote">Shown are the cumulative incidences of any cardiovascular disease (Panel A), a major adverse cardiovascular event (MACE) (Panel B), hospitalization for heart failure (Panel C), death from cardiovascular causes (Panel D), and death from any cause (Panel E) over 6.5 years of follow-up. The numbers plotted below the x axis of each panel are the participants at risk for the outcome at each follow-up time point (i.e., the number of participants in whom a specified outcome event had not developed by that time).</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Microvascular Outcomes in the Intention-to-Treat Analysis.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Cardiovascular and Mortality Outcomes in the Intention-to-Treat Analysis.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/387/12" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 387 No. 12</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 22, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2204705" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Trial of Antisense Oligonucleotide Tofersen for <em>SOD1</em> ALS</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">T.M. Miller and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 22, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2206286" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">S.D. Solomon and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/review-article" class="issue-item_type">Review Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 22, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMra2025746" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Burkitt’s Lymphoma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M. Roschewski, L.M. Staudt, and W.H. Wilson</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2200436%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2200436&amp;pubId=41284272&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2200436%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2200436&amp;pubId=41284272&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id03941196051520012" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6eb03277a01a6-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6eb03277a01a6-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6eb03277a01a6-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6eb03277a01a6-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6eb03277a01a6-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6eb03277a01a6-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6eb03277a01a6-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6eb03277a01a6-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6eb03277a01a6-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6eb03277a01a6-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6eb03187601a6',t:'MTc0OTUzODA1My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6eb03187601a6&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>
<div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>
        
        
    

<div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" data-transactionid="x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" id="captureIFrame_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" target="captureIFrame_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" name="capture_screen"><input id="capture_signIn_js_version_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" name="js_version"><input id="capture_signIn_transactionId_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" data-capturefield="undefined" value="x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" type="hidden" class="capture_transactionId_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" name="capture_transactionId"><input id="capture_signIn_form_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" name="form"><input id="capture_signIn_flow_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" name="flow"><input id="capture_signIn_client_id_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" name="client_id"><input id="capture_signIn_redirect_uri_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" name="redirect_uri"><input id="capture_signIn_response_type_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" name="response_type"><input id="capture_signIn_flow_version_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" name="flow_version"><input id="capture_signIn_settings_version_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" name="settings_version"><input id="capture_signIn_locale_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" name="locale"><input id="capture_signIn_recaptcha_version_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_x4puugekccsnanzcj8jpnt4giz9x96uzs9umntai" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><idb-adjjdhvyuuqv></idb-adjjdhvyuuqv><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2200436?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script></body></html>